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ABSTRACT 
 The signal transducer and activator of transcription (STAT) family of 
proteins is a group of transcription factors that regulate gene expression related to cell 
cycle, cell survival, and immune response. Constitutively active STAT3 has been shown 
to promote the induction and survival of cancer. Given its critical role in both tumor 
onset and progression, STAT3 has emerged as an attractive target for small molecule 
therapeutics. The disparity between assays and assay conditions reported in 
publications for assessing STAT3 inhibitors makes it difficult to compare the potency of 
one compound to another and to determine a ranking of effective inhibitors.  
The purpose of this thesis was to identify small molecule inhibitors that target 
STAT3 directly, and prevent the binding of the DNA-binding domain (DBD) of STAT3 to 
DNA. This project approached this identification and evaluation of inhibitors through in 
silico library screening, development of recombinant assays to quantitatively evaluate 
and rank direct STAT3 inhibitors, and chemical synthesis of STAT3 inhibitors that target 
the DBD of STAT3. 
We successfully established a recombinant protein STAT3/DNA-binding ELISA to 
use in tandem with a recombinant fluorescence polarization assay to identify STAT3 
small molecule inhibitors that target either the DBD or the SH2 dimerization domain. 
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The use of the recombinant ELISA is an essential addition to the field of targeting 
STAT3 activity as it allows for rapid identification of small molecule inhibitors that target 
the DBD. While other methods have been proposed using recombinant STAT3, the 
recombinant ELISA is a modified commercially available colorimetric assay that can 
then be used to standardize the reporting of IC50s against the STAT3 DBD.  
Using our tandem screening method, we identified a novel STAT3 DBD inhibitor with 
an EC50 of 59 nM. This is significant in that other inhibitors in this class have reported 
high micromolar activity for STAT3 inhibition. The design and synthesis of a novel small 
molecule with nanomolar activity demonstrates the feasibility of using computational 
screening, in silico inhibitor design, and a tandem evaluation technique to successfully 
identify small molecules that target the DBD of STAT3. 
 
The form and content of this thesis abstract are approved. I recommend its publication. 
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CHAPTER I 
REVIEW OF THE LITERATURE AND STATEMENT OF PURPOSE1 
STAT3 structure and function 
The signal transducer and activator of transcription (STAT) family of proteins is a 
group of transcription factors that regulate gene expression related to cell cycle, cell 
survival, and immune response [1, 2]. The STAT family of proteins is comprised of 7 
structurally and functionally related proteins STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b, and  STAT6 [1]. Each of the STAT proteins is encoded by a separate gene, 
although all 6 members are structurally similar  [3]. The amino-terminal domain (NH2), 
the coiled-coiled domain (CCD), the DNA-binding domain (DBD), the linker domain, and 
the Src homology 2 domain (SH2) remain highly conserved between the STAT family 
members, while STAT specificity is established by the divergence in the carboxy-
terminal transcriptional activation domain (TAD) (Figure 1.1) [4]. Alternate mRNA 
splicing or proteolytic processes can give rise to multiple isoforms, which have been 
isolated in the cases of STAT1, STAT3 and STAT5, and have demonstrated distinct 
functional relevancies [5]. Akira et al., and Zhong et al., independently discovered 
STAT3 in 1994, classifying STAT3 as an acute-phase response factor that selectively 
bound to the IL-6 response element on DNA within the acute-phase gene promoter [6], 
and determined that STAT3 bound to DNA in response to epidermal growth factor 





Figure 1.1: STAT3 protein structure. A) Global view of the STAT3 homodimer crystal 
structure containing DNA (PDB ID: 4E68) with the individual domains indicated 
(magenta = coiled-coil, orange = DNA binding, blue = linker, yellow = SH2, green = 
transactivation). Middle inset close up of the DNA binding interface with residues 
involved in direct DNA binding highlighted in yellow and those involved in drug binding 
of previously reported DNA binding site inhibitors highlighted in cyan. Bottom inset close 
up of the two interacting SH2 domains (bottom) with the previously reported SH2 
inhibitor binding pockets highlighted. B) An individual STAT3 monomer from the same 
crystal structure. Top inset location of the residues comprising the SH2 domain inhibitor 
binding pockets (pY = red, pY-X = magenta, pY+1 = purple). Middle inset location of the 
redox-sensitive C687 residue and Y705 the target of activating phosphorylation. Bottom 
inset residues involved in direct DNA interaction (yellow) or those reported as the DNA 
binding domain inhibitor interface (cyan).  
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STAT3 is activated through the binding of cytokines or growth factors to cell surface 
receptors [4]. Cytokines such as the interleukins IL-6, IL-10, and IL-11, as well as 
growth factors such as EGF, fibroblast growth factor (FGF), and vascular endothelial 
growth factor (VEGF) can activate the tyrosine phosphorylation cascade [8]. Once 
ligands bind to their corresponding receptors, the receptors form a dimer complex. 
Activation of glycoprotein 130 (gp130) is also initiated, inducing dimerization of gp130 
and the α-receptor subunit of the receptor [9]. Together the ligand receptor and gp130 
complex recruit Janus kinases (JAKs). The aggregation of JAKs leads to their activation 
via phosphorylation which in turn phosphorylates the cytoplasmic tyrosine residues on 
the receptors that serve as a dock for the SH2 domain of STAT3 [10]. STAT3 becomes 
activated (p-STAT3) through the phosphorylation of its Tyr705 residue located within its 
SH2 domain [11]. Activation of STAT3 triggers p-STAT3 to form a homodimer via the 
interaction of the p-Tyr705 of one monomer and the SH2 domain of another [2, 12]. The 
activated dimer dissociates from the receptor and subsequently translocates from the 
cytoplasm to the nucleus where it binds specific DNA sequences and induces 
transcription (Figure 1.2) [12].  The DNA-binding domain of STAT3 has a sequence 
specificity for interferon stimulated response elements or palindromic-γ-activated 
sequence elements very similar to STAT1, with the specific DNA consensus sequence 
being 5’-TTCCCGGAA-3’ [13]. The homology between STAT3 and STAT1 structures 
also aids in heterodimerization of STAT3 and STAT1, and heterodimers can bind similar 
sites in vitro [14]. Transcriptional activity of STAT3 also relies on the binding of co-
activators such as APE/Ref-1, CBP/p300, and NCOA/SRC1a [8]. STAT3 regulates gene 
expression of proteins involved in cell cycle (c-Myc and cyclin D1), anti-apoptosis (Bcl-
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xL, Bcl-2, and survivin), angiogenesis (VEGF and IL-8), and invasion/migration (MMP-2 
and MMP-9) [2, 15]. In addition to JAKs, STAT3 can be activated by non-receptor 
tyrosine kinases such as Src and ABL [16]. 
 
Figure 1.2: Signaling cascade for STAT3 activity. Activation of cell surface receptors 
through the binding of cytokines or growth factors recruits, phosphorylates, and 
activates STAT3. Non-receptor Tyr kinases Src and ABL also activate STAT3. Activated 
STAT3 forms a homo- or heterodimer and translocates from the cytoplasm to the 
nucleus where it binds DNA and co-activators and induces gene transcription. STAT3 
activation is negatively regulated by PIAS, SHP-1/2, SOCS, and PTPRT. 
 
The expression and activation levels of STAT3 vary in normal tissues and cells, 
and STAT3 is highly expressed in the peritoneum, leukocytes of the peripheral blood, 
and neutrophils of the bone marrow. Certain tissues and organs also display higher 
basal levels of STAT3 expression including the peripheral nervous system, digestive 
tract, and bone marrow, suggesting a physiological role of STAT3 that is necessary for 
the function of these systems [8]. The physiological role of STAT3 is generally cell-type 
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and activating cytokine/growth factor-dependent. This is due in part to the induction of 
target genes by STAT3 in different cells and why observable biological impact could be 
proliferation, survival, or apoptosis depending on the target tissue type [13]. While 
knockout of STAT3 in adult tissues results in mild phenotypes, ablation of STAT3 in 
early development results in embryonic lethality, including lethality to embryonic stem 
cells, suggesting physiological importance of STAT3 during embryogenesis [17-19].  
The activation of STAT3 signaling is a controlled and transient process in normal 
cells that can last from half an hour to several hours [20]. Inactivation of STAT3 occurs 
through dephosphorylation of Tyr705 by nuclear protein-Tyr phosphatases such as T-
Cell Protein Tyrosine Phosphatase (TC PTP) and TC45, resulting in the shuttling of 
STAT3 back into the cytoplasm [21, 22]. Additional regulatory mechanisms exist, such 
as the immediate degradation or recycling of cytokine/growth factor receptors following 
the binding of their respective ligands, and the inactivation of JAK, STAT3, and the 
receptor via dephosphorylation through the interaction of the Src homology domain-
containing tyrosine phosphatases 1/2 (SHP-1/2) and the intracellular domain of the cell 
surface receptor [23, 24]. Suppressors of cytokine signaling (SOCS) are transcribed as 
a negative feedback loop as part of STAT3 signaling and interact with the JAK domains 
or intracellular portions of the receptors to reduce STAT3 activation [25]; however, Src-
mediated STAT3 activation is not impacted by SOCS [26]. STAT3 transcriptional activity 
is also regulated through protein inhibitor of activated STAT3 (PIAS), which prevents 
active STAT3 from binding DNA [27], and dephosphorylation of STAT3 at Tyr705 by 
protein tyrosine phosphatase receptor T (PTPRT) [28]. Post translational modifications 
of STAT3, specifically the reversible acetylation of Lys685, have been demonstrated to 
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regulate dimerization status and transcriptional activity of STAT3 in response to 
cytokine stimulation [29]. There have also been reports of STAT3 signaling regulation 
through redox mechanisms targeting activating kinases or STAT3 residues, although 
the benefits or detriments of this regulation are still unclear [30-32]. 
Approximately 70% of human solid and hematological tumors display 
overexpression or constitutively active STAT3 compared with normal cells [4]. It has 
been demonstrated that the induction of oncogenesis in both cultured cells and nude 
mice can be mediated by the expression of mutated STAT3 (STAT3-C) that remains 
constitutively dimerized [33]. By comparison, levels of p-STAT3 expression has greater 
impact on tumorigenesis than total STAT3. Constitutively active STAT3 has been shown 
to promote the induction and survival of cancer [11]. It has been proposed that elevated 
levels of p-STAT3 promote resistance to apoptotic cues and facilitates rapid proliferation 
and tumorigenesis [34]. Recently, it has been demonstrated that activated STAT3 can 
be induced by hypoxia [35], and that the mechanism of action contributing to hypoxia-
induced increases in p-STAT3 levels is a reduction in SOCS3 [36]. Constitutively active 
STAT3 have also been shown to play a role in impairing both the innate and adaptive 
immune responses [37], and STAT3 is constitutively active in both immune cells and 
tumor microglia [38, 39]. Upon recruitment into the tumor microenvironment, M1 
macrophages and microglia become designated as the M2 phenotype following 
exposure to hypoxic conditions [40, 41]. Polarization of tumor-associated macrophages 
(TAMs) towards the M2 phenotype is mediated by the p-STAT3 signaling pathway, and 
ultimately contributes to immunosuppression and tumor invasion [41]. The promotion of 
cancer by TAMs is driven through the secretion of proangiogenic factors such as VEGF 
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and MMP-9, which are downstream targets of STAT3 signaling [42]. Given its critical 
role in both tumor onset and progression, STAT3 has emerged as an attractive target 
for small molecule therapeutics. 
Upstream inhibition of STAT3 
Since the discovery of STAT3, small molecule inhibitors targeting various 
members of the STAT3 signaling pathway have been employed to disrupt STAT3 
signaling and activity. In this section we will briefly discuss selected inhibitors that target 
upstream of STAT3. 
Cell surface receptor inhibitors 
Several growth factors and cytokines have been implicated in the activation of 
STAT3, each involving a specific cell surface receptor. Growth factors known to induce 
the activation of STAT3 include EGF, human epidermal growth factor (HER2), FGF, 
hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), VEGF, and 
insulin-like growth factor (IGF) [8]. Cytokines capable of stimulating STAT3 activation 
include the interleukins IL-6, IL-10, IL-11, as well as IL-6 family members leukemia 
inhibitory factor (LIF) and leptin [15, 43].  Targeting aberrant STAT3 via inhibition of 
cytokine/growth factor binding has been shown to be an effective strategy in a variety of 
systems. EGF receptor (EGFR) inhibitors such as the peptide aptamer KDI1 and small 
molecule PD153035 (Figure 1.3), directly interact with EGFR and inhibit 
phosphorylation of STAT3 at Tyr-705, thus preventing its activation and dimerization. In 
multiple cancer cell lines PD153035 has an IC50 <1 μM and demonstrates specificity for 
EGFR over other growth factor receptors [10, 44]. FGF receptor (FGFR) inhibition with 
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ponatinib (Figure 1.3) also decreases both STAT3 phosphorylation and tumor growth in 
vivo [45]. The clinically approved VEGF receptor (VEGFR) inhibitors include sorafenib, 
sunitinib, and atixinib and have been shown to reduce activation of STAT3 [46]; 
however, most exhibit broad-spectrum kinase activity. Recently, the novel VEGFR-2 
small molecule inhibitor, LCB03-0110 (Figure 1.3) was reported by Kim et al., and 
demonstrated blockage of angiogenesis mediated by VEGF/JAK/STAT signaling [47]. 
The widespread prevalence and importance of the IL-6/JAK/STAT signaling 
pathway in a variety of human malignancies has spurred the development of several IL-
6 and IL-6 receptor inhibitors. Inhibition of IL-6 signaling has been accomplished using 
IL-6 monoclonal antibodies, such as the FDA approved tocilizumab, which has shown 
promising results in rheumatoid arthritis and is currently undergoing pre-clinical 
evaluation in cancer models [48-50]. In contrast, orally available small molecule 
inhibitors of IL-6 have not been extensively explored, likely due in part to the 
development of bacterial infections associated with prolonged blockade of IL-6 due to 
the cytokine’s role in suppressing immune response [51]. Recently, LMT-28 (Figure 
1.3), which was discovered through a library screen by Hong et al., was demonstrated 
to bind to gp130, inhibit IL-6 activation, and downregulate levels of p-STAT3 [52]. 
Another gp130 small molecule inhibitor, SC144 (Figure 1.3), demonstrates inhibition of 
STAT3 activation, reduces expression of downstream targets, and exhibits oral activity 
in ovarian cancer [53]. Although targeting cell surface receptors has demonstrated an 
ability to abrogate STAT3 signaling in response to growth factor or cytokine stimulation, 
a more widely explored strategy has been through the development of kinase small 
molecule inhibitors that target STAT3 phosphorylation.  
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Cell surface receptor inhibitors, particularly those that target VEGFR and EGFR, 
seem to have limited monotherapy benefits [54]. This is due in part to dose limitations 
imposed by toxicities related to high penetration of the central nervous system, 
elevation of liver enzymes, and skin rashes [55]. These adverse effects are the result of 
targeting too far upstream of targeted signaling cascades, and present as broad 
downstream effects beyond desired outcomes. Although targeting cell surface receptors 
has demonstrated an ability to abrogate STAT3 signaling in response to growth factor or 
cytokine stimulation, a more widely explored strategy has been through the 
development of kinase small molecule inhibitors that target STAT3 phosphorylation.  
Kinase inhibitors 
As the majority of STAT3 biological activity is reliant on its activation, a rational 
approach to inhibiting p-STAT3 is through the inhibition of activating kinases upstream 
of STAT3. While there are many protein tyrosine kinases that are capable of 
phosphorylating STAT3, a major area of small molecule development has focused on 
targeting JAK and Src kinases. Over a dozen small molecule JAK inhibitors have been 
developed, many of which are currently in various stages of clinical trial (Figure 1.3). 
Design of JAK inhibitors has centered around two major indications for JAK/STAT 
signaling, namely oncology/hematology and inflammatory syndromes. In both areas 
there have been clinical trials resulting in approved drugs, specifically ruxolitinib and 
tofacitinib, respectively [56]. Other JAK inhibitors such as WP-1066, LS-104, CEP-701, 
LY2784544, and CYT387 (momelotinib) continue into phase I/II clinical trials with each 




Figure 1.3: Chemical structures of upstream STAT3 inhibitors.  
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downstream effects such as increased apoptosis and decreased tumor growth [10, 20, 
56]. However, this approach is not without its problems, a clinical trial of the  JAK1/2 
inhibitor AZD1480 in patients with solid tumors was terminated due to off-target 
neurotoxicity [57]. Other limitations observed in clinical trials for JAK2 inhibitors include 
dose-limiting toxicities associated with anemia and thrombocytopenia [56]. Similar to IL-
6 inhibition, inhibitors of JAK1 and JAK3 also have demonstrated on-target toxicities 
related to increased rates of infection in inflammatory conditions [58]. 
Src was first identified as an onco-protein and is believed to play a critical role in 
cancer progression [59]. Src inhibitors saracatinib (AZD0530), bosutinib (SKI-606), 
dasatinib, and KX2-391 are all in different points of phase II/III clinical trials for multiple 
cancer indications (Figure 1.3).  PP2, another Src inhibitor, inhibits phosphorylation of 
both Src and STAT3 as well as decreases tumor growth through selective inhibition [60, 
61]. Pan-JAK/Src inhibitors have also been explored for more complete targeting of 
STAT3 signaling. E738, a derivative of the natural product indirubin, has IC50 values 
against recombinant JAKs and Src family kinases ranging from 0.7–74.1 nM and 10.7–
263.9 nM, respectively [62]. While indirubin can be obtained from natural sources, 
synthetic bromoindirubins have been developed to enhance their binding affinity for 
kinases such as CDKs, JAKs, and Src family kinases [63]. MLS-2384 is a 6-
bromoindirubin derivative that displays dual JAK/Src inhibition, dose-dependent 
decrease in STAT3 phosphorylation, and anticancer activity in multiple tumor types [63]. 
Although targeting the kinase activity responsible for activation of STAT3 can 
successfully reduce STAT3 activity, off-target toxicities are still a concern related to this 
therapeutic approach. Among the ~500 distinct human kinases, ATP-binding sites 
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remain highly homologous, resulting in off-target kinase inhibition [56]. Furthermore, the 
ability of kinases to activate more than one member of the STAT family can also lead to 
STAT1 and STAT5 inhibition and additional off-target effects. For these reasons, a more 
focused strategy for STAT3 inhibition is through the direct targeting of functional p-
STAT3. 
Direct STAT3 inhibitors 
A number of small molecule compounds directly inhibit the activity and function of 
STAT3 and have been developed for use in cancer treatment and prevention [64, 65]. 
Although the functional outcome is similar, the mechanisms of action of the various 
direct STAT3 inhibitors vary considerably and include disrupting phosphorylation, 
dimerization, nuclear translocation, and/or DNA-binding of STAT3 [66-68]. Several 
prominent examples of these small molecules are discussed in the following sections.  
STAT3 SH2 domain inhibitors 
STAT3 homodimerization is mediated by the protein-protein interactions between 
the SH2 domains of individual monomers, specifically via the phosphorylation of Tyr705. 
This critical molecular interaction has been exploited as a molecular target for small 
molecule inhibitors that directly inhibit STAT3 dimerization [69]. Within the SH2 domain, 
STAT3 has three proximal binding sub-pockets that prove suitable for small molecule 
targeting (Figure 1.1A) [70]. These sub-pockets are comprised of the pY binding 
pocket, containing primarily polar residues responsible for H-bonding and electrostatic 
interactions, and two sub-pockets pY + 1 and pY – X comprising of hydrophobic 
residues, with pY – X being unique to STAT3 (Figure 1.1). The majority of developed 
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STAT3 inhibitors that target the SH2 domain bind at least two of these three 
subdomains [71]. 
One of the first small molecule inhibitors of STAT3 was discovered through a 
high-throughput screen (HTS) of diverse chemical libraries containing a little more than 
17,000 compounds [12]. Stattic (Stat three inhibitory compound) inhibited STAT3 
dimerization (IC50 = 5.1 μM), was selective over STAT1 and STAT5, and prevented 
STAT3 translocation to the nucleus in vitro [70]. The inhibitory activity of stattic was also 
determined to be time-, temperature-, and dithiothreitol-dependent, suggesting 
interaction with cysteine residues such as Cys687 located near the phosphopeptide-
binding area of the SH2 domain (Figure 1.1B) [72]. More recently Zhang et al., 
demonstrated both in vitro and in vivo the treatment of esophageal squamous cell 
carcinoma (ESCC) with stattic radiosensitized cells and xenografts, suggesting a 
potential use as an adjuvant therapy in radioresistant ESCC [73]. Similarly, stattic 
circumvents cisplatin resistance in ovarian cancer [74], suggesting a renewed use of 
this compound in recurrent cancers displaying constitutively active STAT3. 
Song et al., using a structure-based virtual screen of nearly 430,000 molecules, 
identified another STAT3 SH2 domain inhibitor [75]. Their hit compound was identified 
as STA-21 (Figure 1.4), and demonstrated inhibition of active STAT3 binding to DNA, 
suppression of downstream target transcription, and induction of apoptosis in cancer 
cell lines with constitutively active STAT3 expression [75, 76]. This compound was 
subsequently derivatized to form a less complex anthraquinone-based compound (LLL-
3) that possessed comparable anti-proliferative activity as STA-21 and exhibited 
improved cell permeability compared with the parent compound [77]. In K562 leukemic 
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cells, Mencalha et al., demonstrated a decrease in tumor cell survival following 
treatment with LLL-3, as well as a synergistic effect with combination therapy of LLL-3 
and imatinib [78]. Lin et al., further optimized LLL-3, by replacing its acetyl group with a 
sulfonamide and generating the STAT3 inhibitor LLL-12 [11]. This compound was 
determined to have an IC50 against STAT3 in transcriptional luciferase assays and 
traditional STAT3/DNA-binding ELISA ranging from 0.16–3.09 μM in breast, pancreatic, 
and glioblastoma cell lines [11, 79-81].  
An in silico screen of the National Cancer Institute (NCI) chemical libraries 
identified another STAT3 SH2 domain inhibitor, S3I-201 (Figure 1.4). This compound 
was 3-fold more selective for STAT3 over STAT1, blocked the formation of STAT3 
homodimers (EMSA IC50 = 86 μM), and inhibited proliferation of breast and 
hepatocellular cancer cells in mice [67]. Additional computational-based docking studies 
suggested a less than optimal interaction of S3I-201 with the SH2 domain of STAT3. 
These results, taken together with the high micromolar IC50 values in cell-based assays 
(EMSA and ELISA) for this initial hit, prompted the rational design of several analogs of 
S3I-201 in an effort to improve its in vitro activity [82]. Several analogs of S3I-201 that 
showed promise from the SAR studies were SF-1-066, SF-1-087, and SF-1-121 (Figure 
1.4), which had EMSA IC50 values of 37 μM, 24 μM, and 43 μM in DU145 cells, 
respectively [2, 82]. SF-1-066 was determined to bind the SH2 domain of STAT3 with a 
Kd= 2.74 μM, blocked the association of STAT3 with EGFR, inhibited growth of 
malignant cell lines with constitutively active STAT3, and suppressed the expression of 
downstream targets of STAT3-regulated genes [2]. Additional SAR studies derivatized 
the sulfonamide moiety of SF-1-066 and an additional 15 analogs were developed. This 
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study led to the identification of BP-1-102 (compound 17o), a compound that disrupted 
STAT3-DNA complex formation with an IC50 of 6.8 μM, a 5-fold improvement from SF-1-
066 [34, 83]. The highest potency of this compound was determined to be 10 μM in 
MDA-468 breast cancer cells (determined via MTS), inhibited growth of xenografts at 3 
mg/kg, and displayed oral bioavailability, a first for designed STAT3 inhibitors [34]. 
 




More recently S3I-1757, another S3I-201 analog, was developed by Zhang and 
colleagues (Figure 1.4) [84].  S3I-1757 was tested against the STAT3 SH2 domain and 
was found to have an IC50 of 13 μM [85]. In both breast and lung cancer cell lines S3I-
1757 decreased nuclear levels of active STAT3 as well as decreased the ability of 
activated STAT3 to bind DNA in a dose-dependent manner beginning at 50 μM [85]. 
MDA-MB-468 cells transfected with STAT3-C, a genetically engineered mutant capable 
of forming constitutively active STAT3 dimers via disulfide bonding in the absence of 
tyrosine phosphorylation, were able to rescue the inhibition of STAT3 transcriptional 
activity caused by S3I-1757. These data provided further support that S3I-1757 targets 
specifically at the SH2 domain of STAT3.  
From the inception of designing STAT3 SH2 domain inhibitors, there was a need 
to evaluate the effectiveness of these small molecules against STAT3 activity. 
Unfortunately, the lack of uniformity of assays used to determine potency varies among 
publications, making the ranking of different classes of STAT3 inhibitors difficult. Schust 
and Burg developed the fluorescence polarization (FP) assay critical for evaluating 
small molecules as SH2 domain inhibitors against recombinant STAT3 protein. This 
assay uses competitive binding of a small fluorescent peptide that corresponds to the 
gp130 subunit of the IL-6 receptor and has been demonstrated to have a high affinity for 
the SH2 domain of recombinant STAT3 [86]. Interruption of the fluorescence-labeled 
SH2 peptide on the STAT3 protein is indicative of a compound binding to the SH2 
domain of STAT3. This method allows for moderate-throughput screening of chemical 
libraries to identify potentially novel SH2 domain inhibitors of STAT3. Alternatively, 
several groups have utilized time-resolved electrospray ionization mass spectrometry 
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(TRESI-MS) and hydrogen-deuterium exchange (HDX) techniques to assess binding of 
an inhibitor to recombinant STAT3 as well as to evaluate its binding location and affinity 
for STAT3 [87-90]. 
The inhibition of cellular STAT3 activity by SH2 domain inhibition can be 
determined by STAT3 luciferase activity assay and electromobility shift assay (EMSA). 
These assays determine the overall abatement of STAT3 transcriptional activity and 
binding of STAT3 to DNA, respectively. STAT3 enzyme-linked immunosorbent assay 
(ELISA) kits are also available to evaluate the effect of the STAT3 inhibitors on the 
ability of STAT3 to bind DNA. However, methods surrounding dosing with compounds 
remain unclear and there appears to be disparity on whether dosing previously 
prepared nuclear extracts has the capacity to disrupt functional dimers of STAT3. While 
useful in evaluating an inhibitor’s impact on STAT3, cell-based assays do not definitively 
display SH2 domain targeting or determine off target effects within the STAT3 signaling 
cascade. 
Less than 6 years after the initial discovery of the role of STAT3 in malignant 
transformation, peptides and peptide mimics of pTyr peptide PpYLKTK that bind the 
SH2 domain and prevent dimerization and STAT3 activity have been developed [91]. 
Due to their lack of membrane permeability and stability [69], the attractiveness of 
nonpeptidic small molecule STAT3 inhibitors became the forefront of drug discovery. 
Despite these efforts, most small molecule SH2 domain inhibitors remain in pre-clinical 
development [92], with the exception of STA-21 which has completed phase I/II trial for 
psoriasis [93]. One of the major reasons for this is that STAT3:STAT3 dimerization is a 
protein-protein interaction involving a large surface area that is difficult to impact with 
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small molecules [85]. Furthermore, selectivity and mechanisms of effects still remain to 
be clearly defined [69]. Morlacchi et al., recently examined STA-21 and its analogs in a 
FP assay and determined that STA-21 showed no affinity for the SH2 domain of STAT3 
up to 100 μM [94]. Morlacchi et al., demonstrated the ambiguity in the proclamations of 
an SH2 domain inhibitor without crucial assays that evaluate SH2 domain binding and 
affinity. Although promising, many of these compounds still display medium-to-high 
micromolar activities, suggesting the need for additional optimization before 
consideration for in vivo efficacy and transition into clinical trials. Taken together, small 
molecules that target the SH2 domain have been slow to progress to clinical 
development due to the difficulties in targeting the protein-protein interaction and the 
high concentrations required for STAT3 inhibition which increases the likelihood for off-
target toxicities. 
STAT3 DNA-binding domain inhibitors 
While STAT3 SH2 domain small molecule inhibitors remain the leading focus for 
drug discovery, there has been a recent interest in targeting the DBD of STAT3 [69, 95, 
96]. As a transcription factor, STAT3 activity relies on the physical interaction of an 
active STAT3 dimer with its corresponding DNA-binding consensus sequence (Figure 
1.1A). Each monomer within an active STAT3 dimer has a total of four loops, 3 from the 
DBD and 1 from the linker domain that form interactions with the double helix of DNA 
[8]. Platinum compounds are known to form DNA adducts and can disrupt the ability of 
STAT3 to bind DNA, leading to apoptosis in STAT3 dependent human cancer cell lines 
[97, 98]. Platinum compounds proposed as STAT3 inhibitors are classified as platinum 
(IV) complexes and differ from chemotherapeutics such as cisplatin, a platinum (II) 
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complex, which displays no inhibitory effect on STAT3 [97, 98]. The most well-known 
platinum (IV) DBD inhibitors are CPA-1, CPA-7, and platinum (IV) tetrachloride. More 
recently another platinum (IV) compound, IS3-295 was determined to inhibit the DNA-
binding capacity of STAT3 although its mechanism of action still requires 
elucidation.[10] A more thorough review on this class of compounds can be found in a 
manuscript by Yue and Turkson [69]. 
Similar to targeting the SH2 domain of STAT3, several research groups have 
identified peptides capable of disrupting the DBD of STAT3. DBD-1, a small peptide 
aptamer, disrupted STAT3-DNA binding, but did not interfere with STAT3 
phosphorylation. Significant levels of apoptosis were measured in B16 murine 
melanoma cells; however, in vivo findings showed only weak interactions of DBD-1 and 
the DBD of STAT3 [99]. HIC1 (hypermethylated in cancer 1), a tumor suppressor gene, 
was found to endogenously form a complex with the DBD of STAT3 and ultimately 
prevent the binding of STAT3 to its promoter sequence and induce transcription of 
downstream targets. The interaction of HIC1 and STAT3 was identified via mass 
spectrometry and confirmed using immunoprecipitation techniques using Flag-tagged 
HIC1 and HA-tagged STAT3 proteins in HeLa cells [100]. 
More recently, Huang et al. identified InS3-54 through a virtual screening of the 
ChemDiv chemical libraries (Figure 1.4). InS3-54 exhibited a dose-dependent decrease 
in STAT3 activity as determined by luciferase assay (IC50= 13.8 μM). It was also 
determined that InS3-54 displayed selectivity for STAT3 over STAT1 [96] as observed 
in the decrease of downstream STAT3 target transcription and the induction of 
apoptosis in both breast and lung cancer cell lines. This prompted the optimization of 
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InS3-54 as a DBD inhibitor of STAT3. Through an additional structural comparison of 
the ChemDiv database, Huang et al., identified 79 commercially available compounds 
that showed at least 80% structural similarity to InS3-54. Of these compounds, several 
had better anti-STAT3 activity compared with the parent compound and further testing 
isolated compounds InS3-54A18 and InS3-54A26 (Figure 1.4) as lead candidates [95]. 
Both InS3-54A18 and InS3-54A26 displayed cytotoxicity IC50 values of ~4 μM; however, 
InS3-54A26 was disqualified from further study due to poor solubility properties and also 
having an IC50 of 4 μM in non-cancerous lung fibroblast cells giving this compound too 
narrow of a therapeutic window [95]. In contrast, InS3-54A18 had an IC50 in non-
cancerous cells ranging from 7.0–10.5 μM, an IC50 of 11 μM in a STAT3 luciferase 
assay, associated directly with STAT3, and was tolerated by mice up to 200 mg/kg with 
a multiple dosing regimen [95]. InS3-54A18 warrants further study and optimization as a 
DBD inhibitor of STAT3. 
While there are several means of evaluating STAT3 inhibitors that bind to the 
SH2 domain, the breadth of assays available to confirm binding to the DBD of STAT3 
remains quite narrow. An inhibitor of the STAT3 DBD will demonstrate effects in both a 
luciferase assay and an EMSA, similar to an SH2 domain inhibitor. While the FP assay 
for the SH2 domain has been well established, a similar recombinant protein assay 
evaluating compounds that bind the DBD has not yet been developed. This may be in 
part due to the only recent interest in targeting what many regard as an “undruggable” 
domain [95]. A novel approach to this issue was presented by Zhang et al., where the 
use of CNBr-activated Sepharose beads conjugated with their compound InS3-54A26 
and recombinant STAT3 protein identified the domain of binding in a pull-down assay. 
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By incubating the conjugated beads with recombinant STAT3 containing only specific 
domains, Zhang and colleagues were able to demonstrate that at the removal of the 
DBD, the conjugated beads were no longer successful in pulling down the recombinant 
protein [95]. A major limitation of this assay is the requirement that the compound is 
capable of conjugation to the beads in such a way as to maintain interaction with 
STAT3. Further development of assay systems to quantitatively evaluate inhibitors of 
the DBD of STAT3 is needed before HTS methods can be employed effectively to 
identify novel STAT3 DBD inhibitors. While the SH2 domain has been widely explored, 
inhibitors targeting the DBD and more recently the N-terminus have had minor 
development [69] and exploration of these domains is warranted for further STAT3 
inhibitor development. 
Applications of STAT3 inhibition 
STAT3 is constitutively active in many human solid and hematological tumors. 
These include ovarian, cervical, endometrial, breast, colon, pancreatic, lung, brain, 
glioma, head and neck squamous cell carcinoma, renal, prostate, melanoma, 
lymphoma, and leukemia. Most cultured human cancer cell lines also maintain 
constitutively active STAT3. Though the role of STAT3 in tumorigenesis continues to be 
elucidated, STAT3 continues to be a favorable drug target for cancer therapies. 
Likewise, there is significant evidence implicating the activation or suppression of 
STAT3 signaling in several non-cancerous disease states [8], contributing to the 
development of rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, 
and both renal and pulmonary fibrosis.  
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Both RA patients and RA mouse models exhibit hyperactivation of STAT3 [101]. 
In mice, enhanced STAT3 activation promoting RA development has been reported in 
conjunction with the amino acid substitution Y759F in gp130 [102]. This substitution has 
also been demonstrated to be linked to IL-6 stimulation and loss of the negative 
feedback loop mediated by SOCS3 [102]. In humans, p-STAT3 expression is 
significantly increased in peripheral blood fibrocytes and the abnormal growth and 
survival of RA synoviocytes is linked to STAT3 activity [8]. Abnormal STAT3 and/or p-
STAT3 expression is observable in IBD with patients displaying elevated STAT3 activity 
in their intestinal epithelial cells [103]. Peripheral blood granulocytes also display a 2-
fold increase of p-STAT3 expression levels in active versus remissive patients [104]. 
Crohn’s disease is characteristic of having increased expression and nuclear 
localization of STAT3 and treatment with antisense STAT3 oligonucleotides decreased 
proinflammatory cytokines and reduced colonic tissue damage in a mouse colitis model 
[105]. Taken together, these results indicate that STAT3 is also a viable drug target in 
autoimmune and inflammatory diseases and suggest a greater clinical scope for small 
molecule STAT3 inhibitors beyond cancer chemotherapy. 
Disruption of STAT3 signaling delays wound healing in normal mice, while 
constitutively active STAT3 in keratinocytes can induce spontaneous development of 
psoriatic-like skin lesions that can be reversed by STAT3 disruption [106, 107]. 
Similarly, inhibition of JAK/STAT signaling with compound WP1066 suppressed the 
onset of psoriasis in PPARβ/δ transgenic mice [108]. In human patients, a completed 
clinical trial (ClinicalTrials.gov identifier: NCT01047943) of topical treatment of psoriatic 
lesions with small molecule STAT3 inhibitor STA-21 displayed improvement after 2 
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weeks of treatment [93]. STAT3 has also been implicated in the development of renal 
and pulmonary fibrosis. In renal fibrosis, p-STAT3 is overexpressed in tubular epithelial 
cells, myofibroblasts, and interstitial cells and inhibition of STAT3 has been 
demonstrated to induce apoptosis in renal fibroblasts of obstructed kidney [8, 109]. 
Silica-exposed COPD mouse models and human COPD patients exhibit overexpression 
of STAT3 in several airway tissues and downstream gene targets of STAT3 have been 
employed as biomarkers of COPD [110]. 
It is important to note that the role of STAT3 is not entirely limited to disease 
formation and progression, but is also involved with cardioprotection, liver protection, 
and obesity. In transgenic mice, cardiac-specific, constitutively active STAT3 provides 
protection from myocardial ischemia/reperfusion injury, while attenuation of fibrosis after 
myocardial infarction could be achieved through IL-11-mediated activation of cardiac 
STAT3 [111, 112]. STAT3 also displays a protective role in liver injury. Inactivation of 
STAT3 in hepatic cells of mice that are multidrug resistance 2 knockouts (mdr2-/-) 
displayed bile acid induced hepatic injury and fibrosis [113]. In obesity, neuronal STAT3 
activation in response to leptin is necessary for maintaining energy homeostasis. 
Deletion of neuronal STAT3 or disruption of STAT3 activation by the leptin receptor 
(LEPRb) causes severe hyperphagia and morbid obesity. Activation of STAT3 via the 
binding of leptin downregulated the expression of both the obesity-associated and fat-
mass genes in vitro and in vivo [114]. The disruption of STAT3 signaling may have long-





Purpose and significance of the study 
The future of STAT3 small molecule inhibitor development is reliant on the 
standardization for the evaluation of efficacy. The disparity between the assays and 
assay conditions reported in publications for assessing STAT3 inhibitors makes it 
difficult to compare the potency of one compound to another and to determine a ranking 
of effective inhibitors. While cell-based standards such as ELISA, luciferase, and EMSA 
evaluate the ability of an inhibitor to impact STAT3 signaling and activity, they provide 
little to no information on the direct binding to STAT3 and the results can vary 
depending on the cell type used. The recombinant protein pull-down method proposed 
by Zhang et al., [95], lends suggestion on location of binding, yet is limited by its inability 
to increase the throughput of the assay to accommodate larger chemical libraries. The 
development of additional recombinant STAT3 assays to evaluate direct STAT3 binding 
and inhibition is essential for the advancement of the field.  
While the pre-clinical evidence of direct STAT3 inhibition justifies further 
development of novel small molecule therapeutics, there are currently no direct STAT3 
inhibitors in clinical trial for cancer therapy. Many of the upstream kinase inhibitors have 
demonstrated the effects of STAT3 signaling inhibition in cancer suggesting a 
therapeutic relevancy for STAT3 inhibitors. Furthermore, the aberrant activity of STAT3 
in cancer provides potential therapeutic strategies for increasing tumor selectivity of 
STAT3 inhibitors, as the signaling of STAT3 is primarily a transient process in normal 
tissues. With several upstream inhibitors progressing into the final stages of clinical 
trials for various cancer indications, the novelty of STAT3 inhibition is in the direct 
targeting of STAT3. The development of small molecule inhibitors against STAT3 is still 
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an evolving field with the potential to exploit constitutively active STAT3 in cancer and 
other diseases; therefore, the continued development of effective and targeted STAT3 
inhibitors is necessary to elucidate clinical candidates and further illuminate the 
therapeutic significance of STAT3 inhibition. 
The purpose of this thesis is to identify small molecule inhibitors that target 
STAT3 directly, and prevent the binding of the DBD to DNA. This project approached 
this identification and evaluation of inhibitors in the three following ways: 
1. In silico screening of small molecule compound libraries in conjunction with 
computational modeling to identify and develop candidate inhibitors 
2. Development of recombinant assays to quantitatively evaluate and rank direct 
STAT3 inhibitors 
3. Chemical synthesis of STAT3 inhibitors, evaluation of their mechanism of 
STAT3 inhibition, and assessment of structure activity relationships of small 





IN SILICO SCREENING TO IDENTIFY STAT3 DNA-BINDING DOMAIN INHIBITORS 
AND EVALUATION AGAINST CONSTITUTIVELY ACTIVE STAT3 IN CELLS 
Introduction 
Advancement of potent therapeutics is the definitive outcome of cancer research 
[77, 115], but the process is both expensive and laborious [116-118]. Reduction of the 
time and costs associated with drug development has been mitigated using structure-
based computational techniques [67, 75, 119]. These include virtual screening [120], 
molecular docking [121], and molecular dynamics [122]. While computational modeling 
is not the only tool used in drug discovery and development, these techniques prove 
useful in visualizing potential compound-target interactions and predicting novel 
compound modifications to improve affinity for a target receptor [123]. 
The most prevalent form of adult primary tumors of the central nervous system 
(CNS) are collectively referred to as glioma and are thought to originate from supporting 
and/or glial cells of the CNS [124]. The most aggressive form of malignant glioma is 
glioblastoma (GBM) [39], accounting for approximately 50% of all adult CNS tumors and 
is associated with a poor prognosis [124]. The 5-year survival rate is currently less than 
10%, with approximately 16% of patients surviving two years from first diagnosis [125, 
126]. The median survival rate is 14.6 months [39, 124, 127]. Diagnostic criteria for 
GBM include high mitotic activity, microvascular proliferation, and necrotic areas [128]. 
The current standard of care for GBM includes surgery when possible, radiation, and 
chemotherapy [39, 129], with temozolomide (TMZ) as the first-line chemotherapeutic 
27 
 
agent [125]. However, due to the diffuse and invasive nature of these tumors, there is a 
high incidence of recurrence even after successful tumor resection and recurring tumors 
are often TMZ resistant [39, 130, 131]. Levels of p-STAT3 have been correlated to TMZ 
resistance in GBM [132], and treatment of GBM tumors with STAT3 inhibitors has 
demonstrated pre-clinical improvement of therapeutic outcomes [133]. This is in part 
due to a correlation between levels of p-STAT3 and the DNA repair protein O6-
methylguanine-DNA-methyltransferase (MGMT) [131]. MGMT is a suicide enzyme 
responsible for restoring the guanine residues of DNA that are methylated by TMZ 
[134]. Glioblastoma cell line U87 has been demonstrated to have constitutively active 
STAT3 and the expression of p-STAT3 can be manipulated with STAT3 inhibitors [133, 
135]. For this reason, U87 cells have been used as a model cell system for evaluating 
STAT3 inhibition in GBM. 
While U87 cells are used for evaluation of STAT3 inhibition in GBM, HeLa cells 
are frequently used to model STAT3 inhibition regardless of cancer type [136-139]. This 
is partly because HeLa cells display constitutively active STAT3, which can be regulated 
through the treatment of cytokines such as interleukin-6 (IL-6) [140, 141]. The wide 
acceptance of the HeLa cell model prompted us to examine small molecule-mediated 
STAT3 inhibition in this cell type as well. Constitutive activation of STAT3 is not unique 
to glioblastoma and therefore HeLa cells may be a highly applicable cell model for 
evaluating future small molecule inhibitors of STAT3. 
In this chapter, in silico small molecule docking and computational analysis were 
employed to identify small molecules with the potential to inhibit STAT3 from binding 
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DNA. This chapter also establishes a model for cell testing following the identification of 
STAT3 DBD inhibitors. 
Materials and methods 
Library preparation and compound docking 
 Computational-based molecular docking simulations were performed using 
Discovery Studio (BIOVIA, Inc.) and Maestro 9.4 (Schrödinger, Inc.). The crystal 
structure of STAT3 was downloaded from the protein data bank (PDB ID: 4E68) [142]. 
Using Discovery Studio, water molecules and DNA was removed and the remaining 
protein structure was saved as a SDF file which was then imported into Maestro for 
protein preparation. The STAT3 protein was prepared by assigning bond orders, adding 
hydrogens, creating di-sulfide bridges, and repairing any broken or missing amino acid 
sequences. To complete protein preparation, restrained minimization of the protein 
structure was performed using the default constraint of 0.30 Å RMSD and the 
OPLS_2005 force field [143]. While the protein was being prepared, the LigPrep wizard 
was used to prepare the compound libraries that would be docked into STAT3. The 
Selleckchem compound libraries screened were the following: Pharmacologically Active 
Chemicals, Pfizer Licensed Compounds, Apoptosis Compounds, PI3K Signaling 
Inhibitor, Cambridge Cancer Compounds, Tyrosine Kinase Inhibitors, Anti-cancer 
Compounds, Inhibitor, and Kinase Inhibitor libraries. Ligands in each library were 
prepared by generating possible states at target pH 7.0 using Epik and generating 
tautomers, while retaining specified chiralities, and finishing with minimization by 
applying the OPLS_2005 force field [143]. 
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 The prepared STAT3 protein was subjected to SiteMap generation that identified 
the top-ranked potential receptor binding sites, with the top five sites reported as output. 
From this output, the receptor site located within the DNA-binding region of the protein 
was selected and a docking grid was generated using Receptor Grid Generation. 
Prepared ligand libraries were then docked into the grid generated on STAT3 using 
Ligand Docking in XP (extra precision) mode and included post-docking minimization. 
The docking output for each library was evaluated and the top ten individual compounds 
were selected based on highest XP Gscore. All 90 compounds were evaluated 
manually in Discovery Studio to assess binding orientation, hydrogen-bonding 
interactions, and residue interactions with or without DNA bound to the protein.   
Fluorescent polarization assay 
FP assay was conducted as previously reported [85, 86, 144]. Briefly, assay 
buffer (10 mM HEPES, pH7.5, 50 mM NaCl, 1 mM EDTA, 2 mM DTT, and 0.01% 
Triton-X100), 100 nM of full length GST-tagged human STAT3 protein (Abcam), and 
varying concentrations of S3I-1757, A18, A26, stattic, or niclosamide were incubated for 
1 hour at room temperature with mild agitation in 96-well half area black plates 
(Corning). Fluorescent peptide 5-FAM-G(pTyr)LPQTV-CONH2 (Genscript) was added to 
each assay well at a concentration of 10 nM. Final well volumes were 30 µL. Following 
incubation with fluorescent peptide for 30 minutes at room temperature with mild 
agitation, plates were examined using FP Fluorescein Dual module with excitation filter 
FITC FP 480 and emission filter FITC FP P-pol535 and S-pol535. Data was expressed 
as percent control using the equation %C = (mPdrug-mPfree)/(mPSTAT3-mPfree)*100 where 
mP is the value for FP measurement. 
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Cells and reagents 
Human cervical carcinoma cells (HeLa) were obtained from ATCC and were 
verified by the vendor. U87 cells were generously gifted from Dr. Nicholas Foreman, 
and were originally obtained from ATCC. Cells were grown in Eagle's Minimum 
Essential Medium (EMEM) supplemented with 10% heat inactivated FBS. Human GBM 
and normal temporal lysates were also generously supplied by the Foreman laboratory. 
Quercetin was generously gifted by Dr. David Siegel from the laboratory of Dr. David 
Ross. All other compounds were purchased from commercially available sources. 
Western blotting 
Whole cell lysates were prepared by sonication, and a total protein quantity of 50 
μg of each sample was loaded for SDS-PAGE. Antibodies for immunoblotting were 
purchased from Cell Signaling (p-STAT3 [Y705] and STAT3), Sigma-Aldrich (β-Actin), 
and GE Healthcare (ECL antimouse and ECL antirabbit) and used according to 
recommended protocols. The chemiluminescent signal (Thermo Scientific, SuperSignal 
West Pico) was captured using X-ray film [145]. 
IL-6 stimulation of HeLa cells 
 HeLa cells were plated in sterile 6-well plates at a density of 1 million cells per 
well and were incubated for 24 hours. IL-6 diluted in media at a final concentration of 
100 ng/mL was added to each well and allowed to stimulate cells for 1, 2, and 4 hours. 
At the end of each time point, cells were collected and cell lysates prepared. Samples 
were evaluated via Western blot for p-STAT3 (Y705), total STAT3, and β-Actin loading 
control. For evaluation of HeLa cells treated with compound in an electromobility shift 
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assay, confluent 100 mm plates were stimulated with IL-6 at a final concentration of 100 
ng/mL for 1 hour prior to incubation with compound for 4 hours. 
MTS assay 
U87 or HeLa cells were plated in 96-well plates at a density of 5,000 cells/well in 
100 μL of media and were incubated for 24 hours. Media was then aspirated and 
replaced with 50 μL of media containing various concentrations of compounds ranging 
from 500 μM-0.49 µM. Cells were exposed to compounds for 4, 18, and 72 hours. 
Following drug incubation, 30 μL CellTiter 96 AQueous One Cell Proliferation reagent 
(Promega) was added and plates were incubated for 2 hours. Formazan concentration 
was calculated as previously reported [145] through colorimetric analysis using a 
BioTek Synergy H1 plate reader with absorbance read at 490nm. 
Nuclear extract preparation 
Nuclear extracts were prepared using a nuclear extraction kit (Signosis) 
according to product directions and as previously reported [144]. Briefly, 100 mm dishes 
of cells were washed with 1X PBS and then 1 mL of 1X Buffer I was added and dishes 
were rocked on ice for 10 minutes. Cells were released from the dish using a sterile 
scraper and centrifuged at 1200rpm for 5 minutes at 4⁰C. The supernatant was 
discarded and the pellets were resuspended in 1X Buffer II and shaken on ice for 2 
hours. Samples were centrifuged at 1200rpm for 5 minutes at 4 ⁰C and the resulting 
supernatants containing the nuclear extracts were placed in new microcentrifuge tubes. 




Electromobility shift assay (EMSA) 
 Non-radioactive EMSA was performed using and EMSA assay kit (Signosis) 
according to product directions. Nuclear extracts (5µg) were combined with 1 µL poly 
d(I-C), 2 µL of 5X binding buffer, and diluted in nuclease free ddH2O (Ambion) for a 
volume of 9 µL. Samples were incubated on for 5 minutes prior to addition of the TF 
probe for a final volume of 10 µL. Control samples containing only the TF probe or a 
cold probe control were included. Controls and samples were incubated at room 
temperature for 30 min.  
A 6.5% non-denaturing polyacrylamide gel was cast and ran in pre-chilled 0.5X 
TBE buffer for 10 minutes at 120V. Wells were rinsed prior to addition of samples to 
remove any remaining debris. Samples were loaded, the gel tank was placed on ice, 
and the gel was allowed to run at 100V for 1 hour or until the dye reached 1 inch from 
the bottom of the gel. The completed gel was transferred to a provided membrane in 
chilled 0.5X TBE at 60V for 1 hour. After transfer, the protein-bound and free probe was 
immobilized with a Stratagene UV cross-linker using the auto cross link function. The 
membrane was rinsed with 1X detection was and then blocked in 15 mL of blocking 
buffer for 20 minutes with moderate shaking. Streptavidin-HRP conjugate was diluted 
(1:68 dilution) in 1 mL of 1X blocking buffer, added to the solution of blocking buffer 
covering the membrane, and continued soaking for 45 minutes. The membrane was 
subsequently washed three times in 1X detection wash buffer and developed for 5 
minutes using equal parts of substrate A and substrate B. Excess developing solution 




Statistical analysis was performed using GraphPad Prism 5.0, data for IC50 and 
EC50 curves was normalized, and error bars represent the standard error of the mean 
(SEM). Experiments were repeated in triplicate.  
Results 
In silico screening of Selleckchem compound libraries identifies STAT3 inhibitors 
 Computational screening of the Selleckchem compound libraries screened 4147 
compounds against a binding site detected within the linker domain of STAT3 near 
residues shown to interact with DNA (Figure 2.1A). Maestro assigned docking scores to 
each docked compound and output was ranked from best to worst with the most 
negative numbers representing the best scores. The top ten compounds from each 
library screen were compiled (Table 2.1) and evaluated manually for residue 
interactions, binding orientation, XP Gscores, and current proposed targets. XP 
Gscores differed from docking scores as they not only awarded for favorable 
interactions within the binding site, but also penalized for buried polar groups and frozen 
rotatable bonds. 
 From the top 90 compounds, five compounds were selected for in vitro testing 
(Table 2.2). Quercetin (Figure 2.1B) was selected because it appeared as a top hit in 
more than one library screen (Table 2.1). In addition, its low molecular weight, favorable 
XP Gscore, and proposed targets within the STAT3 signaling pathway made it ideal for 
model validation. Raf265 derivative (Figure 2.1C) was selected as a potential lead 
compound due to its orientation in the binding pocket and available points for 
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modification. Raf265 (Figure 2.1E), although not in the screened libraries, was also 
selected because of its structural similarity to raf265 derivative. Nutlin-3 and XI-006 
(Figure 2.1C and 2.1F) were selected from the apoptosis library based on binding 
orientations and XP Gscores. These compounds were then tested against the SH2 
domain of STAT3 to exclude affinity for the activation domain of STAT3. 
Table 2.1: Top docked compounds from in silico screen of Selleckchem libraries 





Pharmacologically Active Compounds 
  Acarbose 645.60   -12.521602 
  Rutin DAB10 610.52   -10.971227 
  Amikacin hydrate 603.62   -10.865956 
  Hygromycin B 527.52   -9.878368 
  Icariin 676.66 PDE -9.84812 
  Troxerutin 742.68   -9.619738 
  Neohesperidin 
dihydrochalcone 
612.58   -9.473306 
  Neomycin sulfate 712.72   -9.402649 
  Diosmin 608.54   -9.294128 
  NADIDE 663.43   -9.119465 
Apoptosis 
  AT101 578.61 Bcl-2 -6.994568 
  TW 37 573.70 Bcl-2  -6.454723 
  TG1012009 509.67 Flt, JAK, c-RET -4.854891 
  Danusertib (PHA-
739358) 




  Pifithrin-¦Á 367.30 p53 -4.758242 
  Lenalidomide 259.26 TNF-alpha -4.601249 
  Thalidomide 258.23   -4.285883 
  XI-006 279.25 p53, Mdm2, 
DNA/RNA Synthesis 
-4.139941 
  nutlin-3 581.49 Mdm2 -4.088736 
  RITA (NSC 652287) 292.37 p53 -4.076094 
Cambridge 
  (-)-Epigallocatechin 
gallate 
458.37   -9.009614 
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Table 2.1 (cont.) 





  Quercetin 302.24 PI3K, PKC, Src, 
Sirtuin 
-7.668211 
  Adriamycin 
(Doxorubicin 
Hydrochloride) 
579.98 Topoisomerase -7.64079 
  Bleomycin sulfate 1512.62 DNA/RNA Synthesis -7.437185 
  Idarubicin 
Hydrochloride 
533.95 Topoisomerase -7.013647 
  Daunomycin HCL 563.98 Telomerase -6.974858 
  Gossypol 518.55 5-alpha Reductase -6.528998 
  MLN9708 517.12 Proteasome -6.482028 
  Ubenimex 308.37   -6.473105 
  VIDAZA (azacitidine) 244.20 DNA/RNA Synthesis -6.43656 
Inhibitor  
  Icariin 676.66 PDE -9.391343 
  Neohesperidin 610.56   -9.323458 
  Mizoribine 259.22 DNA/RNA Synthesis -8.904068 
  Puerarin 432.38   -8.798091 
     
  Amikacin sulfate 781.76   -8.795189 
  Doxycycline 
Hydrochloride 
480.90   -8.556512 
  Bleomycin sulfate 1512.62 DNA/RNA Synthesis -7.927676 
  Linezolid 477.47 DHFR -7.835347 
  Quercetin 302.24 PI3K, PKC, Src, 
Sirtuin 
-7.668211 
  Aliskiren hemifumarate 1219.59 RAAS -7.592595 
Kinase Inhibitor 
  Pazopanib HCl 473.98 VEGFR, PDGFR, c-
Kit 
-7.718161 
  Quercetin 302.24 PI3K, PKC, Src, 
Sirtuin 
-7.659285 
  AS-703026 431.20 MEK  -6.574935 
  raf265.cdx (derivative) 504.39 VEGFR, Raf -6.129953 
  PD0325901 482.19 MEK  -6.01657 
  Piceatannol 244.24   -5.873778 
  Triciribine (Triciribine 
phosphate) 
320.30 Akt -5.714303 




Table 2.1 (cont.) 





  Barasertib (AZD1152-
HQPA) 
507.56 Aurora Kinase -5.615386 
  PD318088 561.09 MEK  -5.589416 
  AG-490 294.30 JAK, EGFR -5.575237 
Pfizer 
  Adriamycin 
(Doxorubicin 
Hydrochloride) 
579.98 Topoisomerase -7.428972 
  Ellence (Epirubicin 
Hydrochloride) 
579.98 Topoisomerase  -7.122306 
  Miglitol 207.22   -6.943112 
  PD0325901 482.19 MEK  -6.587449 
  Azithromycin 748.98 Others -6.446401 
  T 1030.29 mTOR -6.049752 
  Clindamycin 424.98   -5.773685 
  Betaxolol 307.43 Adrenergic Receptor -5.603153 
  CAVERJECT 
(alprostadil) 
354.48   -5.590225 
  PD318088 561.09 MEK  -5.563396 
PI3K 
  aicar 258.23 AMPK -6.64827 
  Temsirolimus (Torisel) 1030.29 mTOR -6.323825 
  Triciribine (Triciribine 
phosphate) 
320.30 Akt -6.080248 
  BAY80-6946 480.52 PI3K -5.545304 
  BX-912 471.35 PDK-1  -4.912148 
  AS252424 305.28 PI3K -4.837285 
  H-89 519.28 S6 Kinase -4.760578 
  CCT128930 341.84 Akt -4.733883 
  TG100-115 346.34 PI3K -4.708581 
  BX-795 591.47 PDK-1, IKK -4.668296 
Tyrosine Kinase 
  Butein 272.25 EGFR -6.222126 
  OSI 420 415.87 EGFR -6.013456 
  Imatinib Mesylate 589.71 PDGFR, c-Kit, Bcr-
Abl 
-5.726396 






Table 2.1 (cont.) 





  Pazopanib HCl 473.98 VEGFR, PDGFR, c-
Kit 
-5.319559 
  mgcd265 517.60 c-Met, VEGFR, Tie-2  -5.205434 
  NVP-ADW742 453.58 IGF-1R -4.940775 
  Dasatinib 488.01 Src, Bcr-Abl, c-Kit -4.908475 
  CP868569 443.54 PDGFR -4.899784 
  WZ3146 464.95 EGFR -4.845868 
Anticancer 
  Bleomycin sulfate 1512.62 DNA/RNA Synthesis -9.065016 
  (-)-Epigallocatechin 
gallate 
458.37   -8.339418 
  Adriamycin 
(Doxorubicin 
Hydrochloride) 
579.98 Topoisomerase -8.329098 
  Ellence (Epirubicin 
Hydrochloride) 
579.98 Topoisomerase  -7.752424 
  Quercetin 302.24 PI3K, PKC, Src, 
Sirtuin 
-7.677464 
  Arranon (Nelarabine) 297.27 DNA/RNA Synthesis  -7.386165 
  Idarubicin 
Hydrochloride 
533.95 Topoisomerase -7.013647 
  Fludara (Fludarabine 
Phosphate) 
365.21 DNA/RNA Synthesis -6.756855 
  Mitoxantrone 
Hydrochloride 
517.40   -6.753417 
  MLN9708 517.12 Proteasome -6.643293 
 
Table 2.2: Selected top hits for investigation 
Compound MW XP GSCORE 
quercetin 302.24 -7.67 
raf265 derivative 504.39 -6.13 
raf265 518.41 -5.52 
nutlin-3 581.50 -4.62 





Figure 2.1: Selected top hits bound in the target binding pocket near the DNA-binding 
region of STAT3. A) Amino acid residues within the target binding site that were most 
common to the top hits from a computational library screen. Highest ranked binding 
orientations of B) quercetin, C) raf265 derivative, D) nutlin-3, E) raf265, and F) xi-006 
reveal candidate compound for derivatization.  
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Top hits from in silico screen do not bind the SH2 domain of STAT3 in a FP assay 
 The FP assay is a competitive binding assay that evaluates the affinity of a small 
molecule for the SH2 domain of STAT3. Quercetin (Figure 2.2A) and nutlin-3 (Figure 
2.2B) showed no affinity for the SH2 domain of STAT3 at concentrations up to 10µM, 
but demonstrated mild affinity at higher concentrations. Raf265 derivative (Figure 
2.2C), raf265 (Figure 2.2D), and XI-006 (Figure 2.2E) demonstrated no affinity for the 
SH2 domain of STAT3 at concentrations up to 1mM. As raf265 derivative showed the 
best potential for design of new analogs, based on binding orientation in the target 
binding site as well as its lack of activity in the FP assay, it was carried forward into cells 
to be evaluated as a STAT3/DNA-binding domain inhibitor. 
U87 and HeLa cells demonstrate constitutively active STAT3  
 Whole cell lysates of U87 glioblastoma cells were evaluated by Western blot and 
demonstrated constitutively active STAT3 (p-STAT3) (Figure 2.3A). Tumor lysate from 
an adult GBM tumor also displayed constitutively active p-STAT3, while lysate from 
normal temporal tissue had transient p-STAT3 expression (Figure 2.3A). HeLa cells 
also displayed constitutively active p-STAT3, visualized by Western blot (Figure 2.3B). 
Treatment of HeLa cells with 100 ng/mL of IL-6 for 1 hour resulted in an increase in p-





Figure 2.2: Selected compounds do not target the SH2 domain up to 20 µM. FP assay 
to evaluate the affinity of A) quercetin B) nutlin-3 C) raf265 derivative D) raf265 or E) xi-





Figure 2.3: Constitutively active STAT3 in multiple samples. A) Representative Western 
blot for total STAT3 expression and p-STAT3 expression in normal temporal lysate (1), 
GBM tumor lysate (2), and U87 cell lysate (3).  B) Representative Western blot for total 
STAT3 expression and p-STAT3 expression in HeLa cells (1) stimulated with IL-6 for 1 
(2), 2 (3), and 4 (4) hours. 
 
Raf265 derivative increases binding of STAT3 to DNA in an EMSA 
  HeLa cells were treated with raf265 derivative at various concentrations for 4, 18, 
and 72 hours. Following treatment, cells were evaluated for cell viability via MTS. At 4 
and 18 hours no EC50 could be calculated (Figure 2.4A). Incubating HeLa cells with 
raf265 derivative for 72 hours resulted in an EC50 of 40.2 ± 7.1 µM. Confluent plates of 
HeLa cells were stimulated with IL-6 for 1 hour prior to the addition of various 
concentrations of raf265 derivative. Stimulated HeLa cells were treated with raf265 
derivative for 4 hours and nuclear extracts were evaluated for STAT3/DNA-binding by 
EMSA. HeLa cells treated with raf265 derivative demonstrated a dose-dependent 




Figure 2.4: Raf265 derivative increases STAT3-DNA binding. A) HeLa cells treated with 
raf265 derivative for 4, 18, and 72 hours were assessed for cell viability by MTS. B) 
Representative EMSA of HeLa nuclear extracts prepared from HeLa cells stimulated 
with IL-6 for 1 hour prior to incubation with raf265 derivative for 4 hours. C) Structure of 
STAT3 monomer with hydrophobicity surface complexed with DNA and raf265 
derivative (enhanced view). 
Discussion 
 The aim of this project is to target STAT3 at the DNA-binding interface, rather 
than the traditional SH2 domain, in order to enhance specificity of small molecule 
inhibitors as well as overcome some of the challenges in targeting the large dimerization 
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domain [146]. The SiteMap function in Maestro identified five potential binding sites on 
the STAT3 monomer with the potential to be targeted by small molecules. One of the 
sites identified was the SH2 domain and two additional sites that were located near 
residues that interact with DNA, as shown from the crystal structure of STAT3 (PBD ID: 
4E68) [142]. We chose the binding site located within the linker domain, based both on 
its proximity to bound DNA and its structural conformation that suggested a more stable 
binding location compared with the unstructured site in the DBD. 
 Many of the compounds that were ranked as top hits in the Selleckchem library 
docking were not viable candidates for testing following manual assessment of binding 
orientation and compound structure. Bleomycin sulfate, for example, had a favorable 
docking score of -9.06 but, upon inspection, the overall size of the compound excluded 
it from the binding site entirely. Screening large diverse compound libraries mandates 
manual examination of the output in order to effectively identify potential candidates that 
will be used to validate the model and identify a lead molecule for optimization. 
 Of the 90 compounds selected as top hits, five compounds were selected for 
further investigation. These compounds were quercetin, raf265 derivative, nutlin-3, xi-
006, and raf265. The first means of model validation was to test these candidates for 
their affinity for the SH2 domain of STAT3 in the FP assay. If the candidates target the 
DNA-binding region of STAT3 they should have no activity in the FP assay. All of the 
compounds demonstrated no affinity for the SH2 domain up to 20 µM. At concentrations 
greater than 20 µM, quercetin and nutlin-3 demonstrated dose-dependent affinity for the 
SH2 domain. Raf265 derivative, xi-006, and raf265 had no affinity for the SH2 domain 
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up to 300 µM. This data suggests that if these compounds display inhibition of STAT3 it 
is via a mechanism other than inhibition of STAT3 dimerization. 
Several groups have reported that the transcription factor STAT3 is constitutively 
active in various tumor types including GBM, but in normal tissue levels of p-STAT3 
remain transient [4, 15]. Consistent with the literature, both adult GBM tumor lysate and 
whole cell lysate of the GBM cell line U87 demonstrate constitutively active STAT3 
compared to normal tissue. HeLa cells likewise displayed constitutively active 
STAT3.The use of IL-6 to stimulate STAT3 activation in HeLa cells was successful in 
increasing levels of p-STAT3 for 1 hour, which then returned to baseline at 2 hours, 
without greatly impacting the total STAT3 expression. Similar stimulation of U87s with 
IL-6 was attempted, however after higher passage numbers p-STAT3 expression 
became undetectable via Western blotting. For this reason, HeLa cells were used for 
the remainder of cell experiments. 
The top five compounds from the library screens were next evaluated for their 
impact on cell viability at 4, 18, and 72 hours in unstimulated HeLa cells (Curves for 
compounds other than raf265 derivative available in Appendix A). These time points 
were selected for evaluating acute and extended exposure to compounds. Since the 
average doubling time of HeLa cells is 18-24 hours, cells were treated with compounds 
at a time point relevant to a complete cell cycle [147]. Of the top 5 compounds, raf265 
derivative appeared to be the most favorable, had no published molecular targets, and 
showed potential for derivatization as it is a linear compound with several suitable points 
for modification and, from our computational modeling, it can occupy the full length of 
the binding cavity.  MTS data displayed minor impact on cell viability until 72 hours, but 
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following a 4 hour incubation HeLa cells co-stimulated with IL-6, raf265 derivative 
induced a concentration-dependent increase of STAT3/DNA complexes in nuclear 
extracts.  
According to the computational model, the observed results may be due in part to 
an induction of a conformational change within the binding cavity that may stabilize this 
region and enhance interactions with DNA (Figure 2.4C). Another explanation for this 
increase in STAT3 binding to DNA is that raf265 derivative acts against another target 
within the STAT3 signaling pathway and increases the activation of STAT3 and its 
subsequent translocation into the nucleus where it binds DNA. An electromobility shift 
assay is effective in measuring the amount of activated STAT3 capable of binding DNA 
present in nuclear extracts, but it does not give insight into the mechanism of action of a 
small molecule. Unlike the FP assay, which uses recombinant STAT3 and a fluorescent 
peptide to measure affinity of a compound for the SH2 domain of STAT3, the EMSA 
relies on a compound to act on its target in a cellular system. Up to this point a similar 
cell-free recombinant assay to evaluate small molecule inhibitors of the DNA-binding 
domain of STAT3 did not exist. Therefore, we felt that it was critical to establish a cell-
free method for identifying a STAT3 DBD inhibitor rather than continue working to 
elucidate the mechanism of action of raf265 derivative. Additionally, synthesis of raf265 
derivative proved laborious and unsuccessful and further disqualified this compound as 
a lead for optimization. 
In conclusion, the work performed in this study identified a target binding cavity 
on STAT3 within the DNA-binding region where small molecules could potentially bind. 
The binding of small molecules to this target pocket has the potential to mitigate 
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constitutively active STAT3 as a transcription factor, and subsequently reduce the 
impact STAT3 has in the progression of cancer. Finally, this work revealed the need for 
a recombinant assay that can quantitatively assess the ability of a small molecule to 
inhibit STAT3/DNA interactions. 
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CHAPTER III 
EVALUATION OF QUANTITATIVE ASSAYS FOR THE IDENTIFICATION OF DIRECT 
STAT3 INHIBITORS2 
Introduction 
STAT3 is a member of the STAT family of transcription factors that regulate 
many cellular processes including cell growth and survival, and immune response [1, 2, 
148]. The activation of STAT3 is mediated through the binding of cytokines and growth 
factors that stimulate a signaling cascade resulting in the phosphorylation of Tyr705 
within the Src homology 2 (SH2) domain of STAT3, and the formation of active 
homodimers [4, 8, 10-12]. Active STAT3 dimers translocate from the cytoplasm to the 
nucleus where they bind DNA and induce transcription of genes involved in the 
regulation of cell growth and survival [12, 146, 149]. In normal cells this process is 
transient; however, in many solid and hematological cancers STAT3 remains 
constitutively active, promoting tumor survival and progression [11, 34]. This critical role 
in oncogenesis makes STAT3 as an attractive therapeutic target for treating human 
malignancies [69, 146, 149, 150]. 
A number of strategies have been examined to inhibit STAT3 activation, such as 
targeting the activating JAK2 kinase; however, these broad-spectrum approaches often 
result in off-target effects [69, 94, 146, 151]. Therefore, there has been recent interest in 
direct inhibition of STAT3, and this has mainly focused on targeting the SH2 
dimerization domain [94, 152]. The SH2 domain is the location of the activating Tyr705 
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residue and is the protein-protein interface responsible for the formation of 
transcriptionally active STAT3 dimers (Figure 3.1).  
 
 
Figure 3.1: Structure of STAT3 dimer complexed with DNA.  A) Global view of the 
STAT3 homodimer crystal structure containing DNA (PDB ID: 4E68). B) DNA-binding 
domain. Location of the redox-sensitive C367 and C468 residues (magenta) and 
residues involved in direct DNA interaction (orange). C) SH2 dimerization domain. 
Location of the redox-sensitive C687 residue and the target of activating 
phosphorylation Y705. 
 
Small molecules designed to target this domain, such as S3I-1757 (Figure 3.2), aim to 
disrupt the protein-protein interaction of the SH2 domains of activated STAT3 
monomers [69]. Due to the difficulty in developing small molecules capable of disrupting 
protein-protein interactions over a large surface area, while maintaining drug-like 
properties, there are a limited number of SH2 domain inhibitors that have reached pre-
clinical and clinical trials [85, 136, 146, 151]. Stattic was one of the first small molecule 
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inhibitors of STAT3 to be identified [70, 146], and it was initially believed to be a SH2 
domain inhibitor; however, it was later determined that its inhibitory activity was due to 
modification of the protein through covalent interactions with cysteine residues, many of 
which reside in the DNA-binding domain (DBD) of STAT3 (Figures 3.1B and 3.1C) [72, 
90]. Therefore, there has been interest in developing small molecules that disrupt 
STAT3 transcriptional activity by targeting the DBD of STAT3 (Figure 3.1C) [95, 96, 
138]. To date, few small molecules have been reported as STAT3 DBD inhibitors, due 
to the lack of an efficient in vitro screening assay, hindering the drug discovery process. 
It has been proposed that niclosamide, an anthelmintic drug, inhibits the ability of 
STAT3 to bind DNA [138], and the pyrrolone based compounds A18 and A26 have 
been reported as STAT3 DBD inhibitors [95] (Figure 3.2).  
 




Targeting this domain may prove more successful in abrogating STAT3 activity in 
cancer, as these compounds have the potential to inhibit STAT3 transcriptional activity 
regardless of dimerization status  [146]. This prospective success may be due in part to 
the ability of unphosphorylated STAT3 to be transcriptionally active [136, 142, 153], and 
the observation that inhibition of active STAT3 dimers alone may not be sufficient in 
modulating STAT3 activity [95]. 
The cell-based assays used to evaluate STAT3 inhibition with small molecules 
include the STAT3-dependent dual luciferase reporter assay [154, 155], electromobility 
shift assay [96, 138, 142], and measuring expression of gene targets downstream of 
STAT3 signaling [95, 156]. These assays effectively evaluate the inhibitory potential of 
small molecules against STAT3 signaling; however, they provide little to no information 
regarding their site of action or if the inhibition is a direct result of STAT3 inhibition [146]. 
For the purposes of STAT3 inhibitor design and development, these cell-based methods 
of evaluation are uninformative without in vitro assays with the capacity to determine 
direct inhibition of STAT3-DNA binding, the potency of inhibition, and the site of 
interaction. The in vitro fluorescence polarization assay, developed by Schust and Burg 
[86], allows for rapid identification of small molecule inhibitors of recombinant STAT3 
acting at the SH2 domain. Although the FP assay is capable of identifying STAT3 
inhibitors that act at the SH2 domain, it does not identify small molecules that target the 
DBD of STAT3. Nkansah et al., have demonstrated that unphosphorylated STAT3 
(uSTAT3) is capable of binding its corresponding DNA sequence using a protein 
electrophoretic mobility shift assay (PEMSA), supporting the use of recombinant STAT3 
for the evaluation of DBD inhibition; however, small molecule inhibitors were not 
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evaluated via this method [142].  In this chapter, we introduce a modified in vitro DNA-
binding STAT3 ELISA as part of a tandem evaluation approach to elucidate and 
quantitatively assess small molecule inhibitors that target either the SH2 dimerization 
domain or the DBD of STAT3.  
Materials and methods 
Cells and reagents 
HeLa cells were obtained from ATCC and were verified by the vendor. Cells were 
grown in Eagle's Minimum Essential Medium (EMEM) supplemented with 10% heat 
inactivated FBS. Compounds S3I-1757 (AOBIOUS), stattic (ApexBio Tech LLC), and 
niclosamide (Cayman Chemical Co.) were purchased.  
Synthesis of compounds A18 and A26 
Compounds A18 and A26 were synthesized according to previously reported 
methods [95, 157] and were prepared as outlined in Scheme 3.1 using commercially 
available starting materials.  
 
Scheme 3.1: Synthesis of A18 (2) and A26 (3). 
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Scheme 3.1: Synthesis of A18 (2) and A26 (3). Conditions: a) Ac2O, sodium acetate 
(cat.), reflux, 18h; b) 4-aminophenol, toluene, 110 °C, 24h; c) N-(4-
aminophenyl)acetamide, toluene, 110 °C, 5 days; d) 6M HCl, reflux, 24h 
 
Common intermediate (Z)-3-(4-chlorobenzylidene)-5-phenylfuran-2(3H)-one (1). 
A stirred solution of 3-benzoylpropionic acid (500 mg, 2.81 mmol), 4-
chlorobenzaldehyde (473 mg, 3.37 mmol), and sodium acetate (237 mg, 2.89 mmol) in 
acetic anhydride (4 mL) was heated under nitrogen atmosphere at 90-95 ⁰C overnight. 
The reaction mixture was cooled to room temperature, filtered and washed with MeOH 
(5 mL/mmol) and water (5 mL/mmol). The sample was dried in a vacuum oven 
overnight to result in a yellow solid (325 mg, 1.15 mmol, 41%). M.p. 227-230 ⁰C (Lit. 
[158] 228-230 ⁰C); 1H NMR (400 MHz, CDCl3) 6.91 (1H, m, furan-H), 7.40 (1H, s, 
C=CH), 7.46-7.50 (5H, m, phenyl), 7.58-7.60 (2H, m, benzyl), 7.78-7.81 (2H, m, benzyl); 
MS (ES+) m/z  283.2 [M35Cl+H]+,  285.0 [M37Cl+H]+.  
A18 (2). A mixture of compound 1 (150 mg, 0.53 mmol) and 4-aminophenol (58 
mg, 0.53 mmol) in toluene (10 mL) was refluxed for 24 hours. The reaction was 
concentrated in vacuo, resuspended in 6N HCl (5 mL), and refluxed for 24 hours. The 
final solution was neutralized with 6M NaOH and extracted in EtOAc and brine. The 
crude sample was concentrated in vacuo and purified via chromatography 
(MeOH:DCM) resulting in an orange solid (63 mg, 0.17 mmol, 32%). M.p. 210-213 ⁰C; 
1H NMR (400 MHz, DMSO-d6) 6.75 (3H, m, Ar-phenol and furan-H), 6.92-6.94 (2H, m, 
Ar-phenol), 7.32-7.35 (6H, m, phenyl and C=CH), 7.52-7.54 (2H, m, benzyl), 7.89-7.91 
(2H, m, benzyl), 9.62 (1H, s, OH); MS (ES+) m/z 274.2 [M35Cl+H]+,  276.2 [M37Cl+H]+.   
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A26 (3). A mixture of compound 1 (100 mg, 0.36 mmol) and 4-aminoacetanilide 
(54 mg, 0.36 mmol) in toluene (8 mL) was refluxed and monitored for completion by 
TLC (approx. 5 days). The reaction was concentrated in vacuo, resuspended in 6N HCl 
(5 mL), and refluxed for 24 hours. The final solution was neutralized with 6M NaOH and 
extracted in EtOAc and brine. The crude sample was concentrated in vacuo and purified 
via chromatography (MeOH:DCM) resulting in a yellow-orange solid (45 mg, 0.11 mmol, 
30%). M.p. 268-271 ⁰C; 1H NMR (400 MHz, DMSO-d6) 2.05 (3H, s, CH3), 6.79 (1H, s, 
furan-H), 7.04-7.06 (2H, m, Ar-phenol), 7.32-7.35 (6H, m, phenyl and C=CH), 7.37-7.55 
(4H, m, benzyl), 7.90-7.92 (2H, m, Ar-phenol), 10.03 (1H, s, NH); MS (ES+) m/z  415.2 
[M35Cl+H]+,  417.0 [M37Cl+H]+. 
FP assay 
FP assay was conducted as previously reported [85, 86]. Briefly, assay buffer (10 
mM HEPES, pH7.5, 50 mM NaCl, 1mM EDTA, 2mM DTT, and 0.01% Triton-X100), 100 
nM of full length GST-tagged human STAT3 protein (Abcam), and varying 
concentrations of S3I-1757, A18, A26, stattic, or niclosamide were incubated for 1 hour 
at room temperature with mild agitation in 96-well half area black plates (Corning). 
Fluorescent peptide 5-FAM-G(pTyr)LPQTV-CONH2 (Genscript) was added to each 
assay well at a concentration of 10 nM. Final well volumes were 30 µL. Following 
incubation with fluorescent peptide for 30 minutes at room temperature with mild 
agitation, plates were examined using FP Fluorescein Dual module with excitation filter 
FITC FP 480 and emission filter FITC FP P-pol535 and S-pol535. Data was expressed 
as percent control using the equation %C = (mPdrug-mPfree)/(mPSTAT3-mPfree)*100 where 
mP is the value for FP measurement. 
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Recombinant STAT3 ELISA 
Measurement of STAT3 binding to DNA was performed using a TransAM STAT3 
ELISA kit (Active Motif). The TransAM STAT3 ELISA kit provides oligonucleotides 
containing the STAT3 consensus binding sequence immobilized on the ELISA plates. 
The kit was utilized per product directions with the replacement of cellular nuclear 
extracts with recombinant STAT3 protein. Full-length, GST-tagged recombinant human 
STAT3 protein (Abcam) was incorporated into the TransAM STAT3 ELISA kit in 
increasing amounts (0.01 µg–1.0 µg). To each well to be used, 30 µL of Complete 
Binding Buffer was added. To the sample wells was added recombinant STAT3 diluted 
in 20 µL of Complete Lysis Buffer and the plate was incubated at room temperature with 
mild agitation for 1 hour. A blank well containing 20 µL of Complete Lysis Buffer was 
also included. Following the 1 hour incubation, wells were washed 3 times with 200 µL 
of 1X Wash Buffer and then incubated with STAT3 antibody (1:1000 dilution) in 100 µL 
of 1X Antibody Binding Buffer for 1 hour without agitation. Wells were washed 3 times 
with 200 µL of 1X Wash Buffer and incubated with HRP-conjugated antibody (1:1000 
dilution) in 100 µL of 1X Antibody Binding Buffer for 1 hour without agitation. Finally, 
wells were washed 4 times with 200 µL of 1X Wash Buffer and then developed using 
room-temperature Developing Solution for 15 minutes. Stop Solution was added and 
the plate was immediately read for absorbance at 450nm with reference wavelength at 
655nm on a microplate reader.  
Compound evaluation using recombinant STAT3 protein. Full-length, GST-
tagged human STAT3 protein and various concentrations of S3I-1757, A18, A26, stattic, 
or niclosamide were incubated in Complete Lysis Buffer at a final volume of 20 µL 
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containing 0.08 μg recombinant protein for 1 hour with mild agitation. Following 
incubation with STAT3 inhibitors, samples were added to corresponding ELISA wells 
with 30 µL of Complete Binding Buffer and inhibition of STAT3 protein binding to the 
DNA consensus sequence was determined via the previously mentioned method. Data 
was normalized and reported as percent of control. 
Compound evaluation using prepared HepG2 nuclear extracts. Various 
concentrations of S3I-1757, A26, stattic, or niclosamide were incubated in Complete 
Lysis Buffer at a final volume of 20 µL containing 5μg total protein of HepG2 nuclear 
extracts for 1 hour with mild agitation. Following incubation with STAT3 inhibitors, 
samples were added to corresponding ELISA wells with 30 µL of Complete Binding 
Buffer and inhibition of STAT3 protein binding to the DNA consensus sequence was 
determined via the previously mentioned method. 
MTT assay 
HeLa cells were plated in 96-well plates at a density of 5,000 cells/well in 100 μL 
of media and were incubated for 24 hours. Media was then aspirated and replaced with 
100 μL of media containing various concentrations of compounds ranging from 500 μM-
0.0019 µM. Cells were exposed to compounds for 24 hours, following which the media 
was aspirated and 50 μL MTT solution diluted in media was added to each well at a final 
concentration of 1 mg/mL. MTT was exposed to cells for 4 hours, aspirated, and then 
100 μL of DMSO was added to each well. Plates were agitated for 10 minutes prior to 
reading absorbance at 540nm in a microplate reader. Data was normalized and 
reported as percent of control. 
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Nuclear extract preparation 
Nuclear extracts were prepared using a nuclear extraction kit (Signosis) 
according to product directions. Briefly, 100mm dishes of cells were washed with 1X 
PBS and then 1mL of 1X Buffer I was added and dishes were rocked on ice for 10 
minutes. Cells were released from the dish using a sterile scraper and centrifuged at 
1200rpm for 5 minutes at 4 ⁰C. The supernatant was discarded and the pellets were 
resuspended in 1X Buffer II and shaken on ice for 2 hours. Samples were centrifuged at 
1200rpm for 5 minutes at 4 ⁰C and the resulting supernatants containing the nuclear 
extracts were placed in new microcentrifuge tubes. Protein concentrations of samples 
were determined via Bradford assay. 
Cell-based STAT3 DNA-binding ELISA  
HeLa cells were plated at 1 million cells per 100mm dish and incubated for 
approximately 72 hours, resulting in serum-starved confluent plates. Plates were then 
washed with PBS and fresh media was added containing concentrations of A18, A26, 
stattic, or niclosamide for 24 hours. Cells were treated with compound concentrations 
derived from their 24 hour MTT assay EC50 value. The dose-response of niclosamide 
was similarly prepared at concentrations ranging from 1 µM–0.0675 µM. Following 
incubation with compounds, cellular nuclear extracts were prepared.  
Measurement of STAT3 binding to DNA was performed using the TransAM 
STAT3 ELISA kit. Sample wells contained 20 µg of nuclear extracts from treated HeLa 
cells diluted in 20 µL of Complete Lysis Buffer. The ELISA was then performed as 
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described in the recombinant ELISA section. Data was normalized and reported as 
percent of control. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.0, data for IC50 and 
EC50 curves was normalized, and error bars represent the standard error of the mean 
(SEM). Experiments were repeated in triplicate.  
Results 
The STAT3 inhibitors S3I-1757 and A26 bind the SH2 domain of STAT3 in an FP assay 
The FP assay assesses the ability of a compound to bind the SH2 domain of 
recombinant STAT3 and disrupt fluorescein-labeled peptide binding [86]. Stattic inhibits 
STAT3 activity via cysteine alkylation [90] and despite a cysteine residue residing in the 
SH2 domain (Cys687), we did not detect any disruption of STAT3-peptide binding with 
stattic up to 600 µM (Figure 3.3A). S3I-1757 has been reported as an SH2 domain 
inhibitor of STAT3 and our results support that S3I-1757 can bind the SH2 domain and 
prevent protein-protein interactions at this interface, with an IC50 of 7.39 ± 0.95 µM in 
the FP assay (Figure 3.3B). Both compounds A18 and A26 have been reported as 
DBD inhibitors of STAT3 [95]. A18 demonstrated no activity in the FP assay; however, 
A26 exhibited robust inhibition with an IC50 value of 0.74 ± 0.13 µM (Figure 3.3C). 
Niclosamide has also been proposed to target STAT3; however, its mode of action has 
not been confirmed although suggested to target the DBD. From our results, 
niclosamide does not interact with the SH2 domain at concentrations up to 600 µM 
(Figure 3.3C). The compounds that demonstrate no activity in the FP assay (up to 50 
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μM) require an alternative in vitro assay to determine if they exhibit inhibitory action on 
the DBD of STAT3. 
 
Figure 3.3: Fluorescence polarization (FP) assay measures affinity of STAT3 inhibitors 
for the SH2 domain. A) stattic B) S3I-1757, and C) A18, A26, and niclosamide. 
 
Recombinant, full-length STAT3 demonstrates a concentration-dependent increase in 
DNA-binding in a modified ELISA 
The STAT3 DNA-binding ELISA can be used to evaluate the ability of STAT3 in 
cellular nuclear extracts to bind its corresponding consensus sequence that has been 
immobilized on a 96-well plate [159, 160]. Addition of full-length, recombinant 
monomeric STAT3 to the TransAM STAT3 ELISA resulted in a concentration-
dependent increase in optical density (OD). These results demonstrate that OD (y) 
exhibited a linear correlation with the concentration of STAT3 (x), given by the equation 
y = 3.120x+0.1525 (Figure 3.4A). The in vitro ELISA results demonstrated that 
recombinant STAT3 had measurable binding activity and suggested that incorporating 
recombinant STAT3 into the assay may allow for more accurate and direct assessment 




Figure 3.4: Recombinant STAT3 ELISA evaluation and quantification of nuclear STAT3 
bound to DNA in cell extracts. A) Recombinant STAT3 added to TransAM STAT3 
ELISA in increasing concentrations and plotted based on optical density (OD450). B) 
Quantification of nuclear extract samples from loading either 5 µg of HepG2 nuclear 
extracts or 20 µg of HeLa nuclear extracts.  
 
Quantification of STAT3-DNA binding in nuclear extracts 
Using the equation obtained in the previous section, we quantified STAT3 in 
nuclear extract samples that bound the DNA consensus sequence immobilized on the 
ELISA plate. The TransAM STAT3 ELISA kit provides prepared nuclear extracts of 
HepG2 cells stimulated with IL-6 (100ng/mL). The average OD recorded for the 
recommended 5μg total protein of HepG2 nuclear extracts was 0.793, equating to an 
average STAT3-DNA bound content of 0.21μg (Figure 3.4B), although there was 
substantial variability among the different samples. The average OD recorded for 20μg 
total protein of HeLa nuclear extracts was 0.532, equating to an average STAT3-DNA 
bound content of 0.12μg (Figure 3.4B). Based on data consistency, HeLa cells were 
used for the evaluation of inhibitors in cell-based assays. Furthermore, the data 
obtained from the nuclear extracts served as a protein loading guide based on OD. 
60 
 
Stattic, S3I-1757, and niclosamide inhibit recombinant STAT3-DNA binding in a DNA-
binding ELISA 
Recombinant STAT3 was incorporated into a STAT3-DNA binding ELISA to 
determine small molecule binding and disruption of STAT3-DNA binding (Figure 3.5D). 
The cysteine alkylator stattic inhibited STAT3-DNA binding with an IC50 of 1.27 ± 
0.38μM (Figure 3.5A). S3I-1757, which also demonstrated affinity for the SH2 domain, 
inhibited STAT3-DNA binding with an IC50 value of 0.31 ± 0.18μM (Figure 3.5C). A26 
and A18 demonstrated weak inhibition of STAT3-DNA binding at concentrations greater 
than 10μM and no IC50 values could be determined (Figure 3.5B). Niclosamide 
exhibited inhibition of STAT3-DNA binding with an IC50 of 1.93 ± 0.70μM, supporting its 
site of action as the DBD of STAT3 (Figure 3.5B). The compounds that demonstrate 
activity in the FP assay but not the ELISA prevent STAT3 dimerization, those that have 
activity in the ELISA assay but not the FP assay prevent direct interaction of STAT3 
with DNA, and compounds that have activity in both the ELISA and the FP assay are 
mixed mode inhibitors. Once the mode of STAT3 inhibition is known compounds can 
then be evaluated in cell-based assays, even compounds that demonstrate no activity in 
the FP or ELISA assays could be tested in the cell-based assays to determine indirect 
effects on STAT3 activity. 
Niclosamide demonstrates potent inhibition of STAT3 in cell-based ELISA at sub-lethal 
concentrations 
The effect of the various STAT3 inhibitors on cell viability after 24-hour treatment 
was assessed by MTT assay and the EC50 of each compound was determined: stattic 
61 
 
0.29 ± 0.09 μM, A18 12.39 ± 1.2 μM, A26 6.10 ± 1.3 μM, and niclosamide 1.09 ± 0.9 μM 
(Figure 3.6A). No EC50 for S3I-1757 could be determined via MTT and higher 
concentrations of S3I-1757 were not achievable due to solubility issues. 
 
Figure 3.5: Recombinant STAT3 ELISA reveals STAT3 inhibitors that act at the DNA-
binding domain. Recombinant STAT3 incubated for 1h with A) stattic, B) A18, A26, 
niclosamide, or C) S3I-1757 prior to addition to ELISA plate, and D) schematic of 
modified TransAM STAT3 ELISA using recombinant STAT3. Left: Control well 
demonstrating binding of recombinant STAT3 (blue) to corresponding DNA consensus 
sequence to produce maximum OD450 (dark yellow). Right: Representative 
experimental well demonstrating interruption of STAT3 (blue) binding to DNA in the 
presence of a DBD inhibitor (red) resulting in reduced OD450 (light yellow). 
 
Similar to an EMSA, the STAT3 DNA-binding ELISA measures the ability of activated 
STAT3 present in nuclear extracts to bind to its corresponding DNA consensus 
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sequence [159-162]. Therefore, an ELISA performed on cellular nuclear extracts allows 
for the evaluation of compounds that target the SH2 domain and/or the DBD of STAT3. 
STAT3 inhibitory potential of the compounds was assessed by incubating HeLa cells at 
concentrations capable of decreasing cell viability by 50% as determined by MTT, 
followed by preparation of nuclear extracts to evaluate by ELISA. Stattic and A26 did 
not alter STAT3-DNA binding at their respective EC50 concentrations (Figure 3.6B). In 
contrast, both A18 and niclosamide reduced STAT3-DNA binding compared to control 
(55% and 75%, respectively) (Figure 3.6B). An EC50 of 0.19 ± 0.001 µM was 
determined from a dose-response curve for niclosamide in analysis of nuclear extracts 
in the ELISA (Figure 3.6C). 
 
Figure 3.6: Cell-based STAT3 ELISA demonstrates inhibition of STAT3 with 
niclosamide at sub-lethal concentrations. A) MTT of HeLa cells incubated with 
compounds for 24h. B) Cell-based ELISA of HeLa cells dosed for 24h at EC50 as 
determined by MTT. C) HeLa cells dosed with niclosamide (67.5 nM-1 µM) for 24h and 
STAT3 DNA-binding determined by ELISA.  
Discussion 
Direct small molecule inhibitors of STAT3 activity have diverse chemical 
structures and vary by mode of action. Inhibitors of STAT3, particularly those that target 
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STAT3-DNA binding, have been evaluated using cell-based assays, but the results of 
these assays can be difficult to interpret as the mode of action of the compound and the 
way it directly or indirectly affects STAT3 cannot be determined via these methods. 
Furthermore, IC50 values for compounds tested in cell-based assays vary between 
assay and cell-type and may not be representative of the effects of STAT3 inhibition 
alone [146]. Therefore, the expansion of in vitro assays available to evaluate direct 
STAT3 inhibition and inhibitor mode of action is critical for medicinal chemistry efforts 
focused on the advancement of STAT3 inhibitor identification and development. 
A well-established method for evaluating small molecule inhibitors of the SH2 
domain is the FP assay [86]. This competitive binding assay uses monomeric 
recombinant STAT3 and a fluorescent peptide that has high affinity for the STAT3 SH2 
domain [86]. Small molecules targeting this domain impair the binding of the peptide, 
leading to a change in fluorescence based on free versus bound peptide. In the FP 
assay, stattic did not present any observable activity against the SH2 domain up to 600 
µM. Cys687 within the SH2 domain and both Cys367 and Cys468 within the DBD, are 
all potential targets for stattic and alkylation within the DBD may be the primary 
mechanism of action of stattic-mediated STAT3 inhibition [90, 163]. The lack of 
inhibition of stattic at the SH2 domain may be due in part to the inability of stattic to 
disrupt the protein-peptide interaction through the alkylation of Cys687 alone. Similarly, 
the steric bulk of stattic may be insufficient to disrupt STAT3 dimerization. S3I-1757 has 
been reported as a STAT3 SH2 domain inhibitor and has previously been evaluated in a 
FP assay [85]. The IC50 of 7.39 ± 0.95 µM  value obtained from our FP assay data, is in 
good agreement with values reported in the literature [85], and S3I-1757 served as a 
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positive control for this assay. Both A18 and A26 have been reported as DBD inhibitors 
[95], but the activity of A18 or A26 has not been previously reported in the FP assay 
and, as expected, A18 exhibited no inhibition in the FP assay. Interestingly, despite 
significant structural similarities with A18, A26 demonstrated good affinity for the SH2 
domain with an IC50 value of 0.74 ± 0.13 µM. Previous studies utilized immobilized A26 
in a protein pull-down experiment with various domain deletions of recombinant STAT3 
protein to determine the DBD was the binding site of A26. The results of our FP assay 
suggest that this compound may have a bimodal mechanism of action with the capacity 
to bind both the SH2 and DBD sites of STAT3. In contrast, the mechanism of STAT3 
inhibition by niclosamide had previously been proposed to be due to targeting the DBD 
based on results from EMSA analysis [138]. Our results further support that niclosamide 
does not have substantive affinity for the SH2 domain and exerts its inhibitory effects via 
interaction with the DBD, preventing DNA binding and subsequent transcriptional 
activation.  
The DNA-binding ELISA kit from Active Motif has previously been used to 
examine the effect of small molecule inhibitory activity against the binding of activated 
STAT3 present in nuclear extracts of IL-6 stimulated HepG2 cells [161]. In this method, 
nuclear extracts were incubated with compounds, rather than live cells treated with 
compounds prior to nuclear extract preparation. The logic behind this method was that 
treating prepared nuclear extracts with a STAT3 inhibitor would act as a recombinant 
system, while also demonstrating inhibitory activity on the active dimer of STAT3. We 
also performed similar methods with no observable results up to 100 µM using S3I-
1757, stattic, niclosamide, or A26 (data available in Appendix B). This suggests that 
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active STAT3 dimers may have a structural conformation that cannot be disrupted by 
small molecule inhibitors and instead the effectiveness of such inhibitors would need to 
be evaluated against STAT3 monomers prior to dimer formation. 
It has previously been confirmed that recombinant STAT3 can bind to DNA and 
the interaction of uSTAT3 with DNA is similar to the binding orientation of active p-
STAT3 [142]. The recombinant STAT3 ELISA results demonstrated the suitability of this 
assay to both determine the binding of recombinant STAT3 protein and identify potential 
inhibitors of STAT3-DNA binding. The capability of full-length recombinant STAT3 to 
bind its corresponding consensus DNA sequence immobilized on an ELISA plate allows 
the estimation of the amount of activated STAT3 bound to DNA in nuclear extract 
samples. Using the concentration of STAT3 quantified in HeLa nuclear extracts as a 
guide, compounds were evaluated for their DNA-binding inhibitory activity against 
monomeric recombinant STAT3 in the modified ELISA. The compounds selected in our 
study inhibit STAT3 activity with differing modes of action and display inhibition of 
STAT3 in STAT3-dependent luciferase reporter assays [85, 95, 138, 164]. Although 
assay conditions are not uniform across publications, all compounds examined in our 
study reduced STAT3 transcriptional activity to varying degrees.  
Stattic alkylates cysteine residues in the DBD of STAT3 [90, 163], resulting in the 
decreased activity observed in the recombinant protein ELISA. S3I-1757 also showed 
potent activity in the ELISA against STAT3 monomers and this may be due to S3I-1757 
having a bimodal mechanism of action, acting at both the SH2 domain and DBD. 
Niclosamide, A18, and A26 have been suggested as DBD inhibitors, yet only 
niclosamide demonstrated appreciable activity in the recombinant protein ELISA assay. 
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Our results indicate that A18 and A26 do not effectively inhibit STAT3 via binding to the 
DBD. A26 exhibited potent activity in the FP assay and little activity in the in vitro ELISA 
at concentrations up to 50 µM. In contrast to previous reports, A18 had no observable 
activity in either the FP or the in vitro ELISA assays up to 10 µM, suggesting the 
mechanism of action of A18 is not a result of direct STAT3 inhibition, despite structural 
similarity to A26. Since the in vitro ELISA using monomeric recombinant STAT3 does 
not rely on the formation of STAT3 dimers, the primary use of this ELISA method is to 
identify potent inhibitors that target the DBD as opposed to the SH2 domain of STAT3, 
when used in combination with the FP assay. Structural analysis studies using X-ray 
crystallography may further confirm the interaction of niclosamide at the DBD; however, 
there are only 3 crystal structures (PDB ID: 4E68 [142], 3CWG [165], and 1BG1 [166]) 
of the core STAT3 fragment containing the SH2 domain and DBD currently deposited in 
the Protein Data Bank (http://www.rcsb.org) and no STAT3-inhibitor co-crystal 
structures are present, suggesting that the resolution of the STAT3 crystal structure is 
not a trivial endeavor.   
The MTT assay was used to determine the maximum concentration of compound 
that could be used in cells prior to the preparation of cellular nuclear extracts without 
depleting cell numbers such that isolated protein concentrations reside outside of those 
required for detection in the ELISA assay. Dosing cells at a concentration greater than 
the EC50 would result in too few cells remaining to produce the required 20 µg of total 
protein in the nuclear extracts. Although stattic demonstrated inhibition of STAT3-DNA 
binding in the ELISA using recombinant STAT3, no inhibition was observed in the 
ELISA using nuclear extracts, possibly due to the non-specific cysteine alkylation of 
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other cellular proteins. S3I-1757 has previously displayed high micromolar activity in 
cells [85], and no EC50 could be determined from the MTT assay (Figure 3.6A). 
Therefore, S3I-1757 was not advanced forward for the evaluation of STAT3 inhibition by 
ELISA in HeLa cells. A18 induced a ~55% reduction in STAT3-DNA binding at its MTT 
derived EC50 of 12 µM while A26 displayed no significant activity at the corresponding 
concentration of 6 µM. Results reported for a STAT3 EMSA in H1299 cells is consistent 
with a 50% reduction of STAT3-DNA binding for A18 at 12 µM and no reduction in 
binding for A26 at 6 µM [95]. The lack of activity of A18 in the FP assay and the in vitro 
ELISA using recombinant STAT3, but activity in the cell-based ELISA supports a mode 
of action other than direct STAT3 inhibition (Figure 3.7). This highlights the need for 
cell-free systems to evaluate direct STAT3 inhibitors, as treating cells with compound 
can provide confounding results. Niclosamide demonstrated potent inhibition of STAT3 
in the cell-based ELISA with an EC50 of 0.19 ± 0.001 µM. The increased potency of 
niclosamide in the cell-based ELISA suggests that niclosamide may also target other 
members upstream of STAT3, resulting in a greater impact on STAT3-DNA binding. 
This is further supported in the literature, as niclosamide has been investigated for its 
anticancer activity in additional signaling cascades many of which crosstalk with the 
STAT3 signaling pathway [167-170]. 
Taken together, our data support that the FP assay and ELISA using 
recombinant STAT3 can serve as an effective quantitative approach to identify potent 





Figure 3.7: Workflow for the evaluation of STAT3 small molecule inhibitors to determine 
site of action. Arrows indicate assay result as either positive (green) or negative (red). 
 
The use of the FP assay and the recombinant STAT3 ELISA has a number of 
advantages over cell-based methods: 1) it allows the identification of direct STAT3 
inhibitors, 2) by using both assays the site of interaction can be determined, and 3) the 
assays provides dose-response and IC50 data for STAT3 inhibitors allowing an 
evaluation of inhibitory potency; therefore, compounds can be ranked and structure-
activity relationships (SARs) can be established. Furthermore, the data obtained from 
the ELISA using nuclear extracts from HeLa cells provides initial support that STAT3 
inhibitors targeting the DBD are more efficient than those targeting the SH2 domain in 
cellular systems. In this study, we have established an approach for identifying DBD 
inhibitors of STAT3 and our data strongly supports that niclosamide targets the DBD of 
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STAT3. Although niclosamide was not designed or developed as a STAT3 inhibitor, it 
may provide a structural basis for the development of more selective STAT3 inhibitors 






NICLOSAMIDE AND ANALOGS INHIBIT STAT3 AT THE DNA-BINDING DOMAIN 
Introduction 
In the previous chapter we demonstrated the ability of niclosamide to inhibit 
STAT3/DNA-binding in both recombinant and cell-based assays via a mechanism other 
than binding at the SH2 dimerization domain [144]. While our data suggests that 
niclosamide is a potent STAT3 inhibitor, it was not originally designed to target STAT3 
[138, 171]. See Andrews et al., for a more thorough review on the biology and 
toxicology of niclosamide as a  molluscicide [171]. Therefore, there is the opportunity to 
examine structural modifications of niclosamide with the purpose of increasing 
specificity for the STAT3 DBD. 
Huang et al., previously examined a binding site within the amino acid residues 
(residues 329−332, 340−346, 406−412, and 465−468) that correspond to the DBD of 
STAT3 [95]. This site is structurally comprised of β-sheets and has the potential for 
flexibility in solution. Alternatively, we have identified a binding region at the interface of 
the DNA-binding and linker domains (LD) of STAT3 that consists of primarily α-helices 
and may be more structurally rigid. Both sites contain residues that interact with the 
DNA consensus sequence to which STAT3 binds [142], and thus -structure activity 
relationships (SARs) of niclosamide and structurally similar compounds would need to 
be examined to indicate the site of niclosamide inhibition.  
In this chapter, we identified small molecules with >85% similarity to niclosamide 
through a computational screen of the NCI diversity III compound library as well as 
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rationally designed analogs of niclosamide to examine the structural requirements for 
STAT3 inhibition and thus attempt to determine the likely site of action of niclosamide 
from the two potential binding sites located near STAT3-DNA interactions. The 
evaluation of these small molecules in the recombinant ELISA and FP assay and cell-
based ELISAs has allowed the initial development of a SAR and as chemical probes 
these compounds have supported the identification of the targeted binding site.  
Materials and methods 
Cells and reagents 
HeLa were obtained from ATCC and were verified by the vendor. Cells were 
grown in EMEM supplemented with 10% heat inactivated FBS. Niclosamide was 
purchased from Cayman Chemical Company. Small molecules evaluated from the NCI 
diversity library screen were provided by the Developmental Therapeutics Program’s 
chemical repository. All chemical reagents were purchased from the Aldrich Chemical 
Company, Fisher Chemicals or Alfa Aesar Chemicals and were of the highest available 
purity. Chemicals were used as supplied with no further treatment. If chemicals used 
were stated as dry/anhydrous, they were stored in SureSeal™ septum-sealed bottles 
and removed under an inert nitrogen environment, with the reaction being carried out 
under the relevant inert atmosphere. Palladium catalysts were stored and measured out 
under an inert atmosphere. 
Library preparation and compound docking 
Library preparation and compound docking was performed as outlined in Chapter 
2. Briefly, the crystal structure of STAT3 was downloaded from the protein data bank 
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(PDB ID: 4E68) [142] and was prepared using the protein preparation wizard 
(Maestro10.2, Schrödinger, Inc). Ligands were prepared using the LigPrep wizard. The 
prepared STAT3 protein was subjected to SiteMap generation that identified the top-
ranked potential receptor binding sites, with the top five sites reported as output. From 
this output, the receptor site identified in Chapter 2 was selected and a docking grid was 
generated using Receptor Grid Generation. Prepared ligand libraries were then docked 
into the grid generated on STAT3 using Ligand Docking in XP (extra precision) mode 
and included post-docking minimization. An additional binding site located within the 
DNA-binding domain was selected and a docking grid was generated using Receptor 
Grid Generation. Prepared ligand libraries were also docked into the grid generated on 
STAT3 at this site using Ligand Docking in XP mode and included post-docking 
minimization. 
The OTAVA fragment library was prepared and docked into the two identified 
binding sites within the DNA-binding domain of STAT3. Output from this docking was 
used to identify potential modifications to niclosamide and identify structures that may 
favor interaction with one binding site over the other. Niclosamide and the suggested 
analogs were prepared using ChemDraw and imported into Maestro10.2 as a 
compound library where they were prepared as ligands and docked into each binding 
site. Compounds were ranked by XP Gscore from most negative to least negative. 
Diversity library screen with Cresset Forge 
 Small molecule alignments and similarity analysis was conducted using Forge 
10.4 software (Cresset) [172]. The NIH/NCI Diversity III library was aligned to the 
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predicted binding orientation of niclosamide in either the DBD or linker domains and 
similarity calculated by both molecule shape and field characteristics (weighted equally 
in final scoring). Top compounds showing a high degree of similarity to one or both 
references were then tested in vitro to confirm STAT3 inhibitory activity. 
Chemical Synthesis 
Chromatography. Reaction monitoring and compounds identification was aided 
using Thin Layer Chromatography (TLC) and Retardation factor (Rf) values. TLC was 
conducted with Merck aluminum backed Si F254 plates. UV absorbent compounds were 
visualized under short wave (254 nm) UV irradiation. Compound purification was 
achieved using medium pressure ‘Flash’ column chromatography, with the use of 
Davisil silica 40-60μm as the stationary phase, or Biotage automated chromatography 
using pre-packed silica cartridges. A Biotage Isolera automated flash purification system 
was used with UV monitoring at 298 nm and compound collection at 254 nm.  
Analytical Techniques. All melting points were determined using a Stuart 
Scientific SMP40 melting point apparatus and are uncorrected. 1H and 13C nuclear 
magnetic resonance (NMR) spectra were obtained as solutions in deuterated solvents 
DMSO-d6 or CDCl3 using a Bruker Avance III 400 spectrometer recording at 400 MHz. 
Chemical shifts (δ) are reported in parts per million (ppm) and the spin-multiplicity 
abbreviated as: s (singlet), d (doublet), t (triplet), q (quartet), quin (quintet), sept (septet), 




Mass Spectrometry (MS) was carried out on an API 4000. Fourier Transform Infrared 
(FTIR) spectra were obtained using a Bruker Alpha Platinum-ATR as a neat sample. 
Microwave Assisted Synthesis. When stated, reactions were carried out under 
microwave irradiation, in sealed vessels, using the Biotage Initiator Sixty with robotic 
sample bed. Samples were irradiated at 2.45 GHz, able to reach temperatures of 60 - 
250 ºC with a rate of heating at 2-5 °C/sec, and pressures of up to 20 bar. 
General procedure A: Microwave conditions for amide formation. 
 
Scheme 4.1:General synthesis method A  
In an oven dried microwave flask, the required carboxylic acid (1.5 equiv), aniline 
(R3 = NH2) or phenol (R3 = OH) (1 equiv), and POCl3 (1.5 equiv) were combined in 
anhydrous toluene (6 mL/mmol) and heated under microwave irradiation conditions at 
180 ⁰ C for 1 hr. The solvent was removed in vacuo and the crude residue was 




General procedure B: Nitro-reduction of amines. 
 
Scheme 4.2: General synthesis method B 
Tin(II) chloride (4.0 equiv) was added to a mixture of the nitro aromatic (1.0 
equiv) in absolute ethanol (10 ml/mmol). The reaction mixture was heated at reflux for 
1.5 hours, after which the solvent was removed in vacuo. The resulting residue was 
dissolved in EtOAc (20 ml/mmol) and a saturated aqueous solution of NaHCO3 was 
added until the aqueous phase was at pH 9-10. The resulting precipitate was removed 
by filtration through Celite® and the organic phase was collected, washed with brine (5 
ml/mmol), dried (MgSO4) and evaporated to dryness. The crude residue was 
subsequently purified by silica gel chromatography to give the desired compound. 
General Procedure C: Suzuki coupling of boronic acids. 
 
Scheme 4.3: General synthesis method C 
76 
 
 To a stirred solution of 5-chloro-4-iodo-2-methoxybenzoic acid (1 equiv) in 
anhydrous toluene (10 mL/mmol) was added the required boronic acid (1.2 equiv) and 
K2CO3 (5 equiv). This mixture was treated with Pd(PPh3)4 (0.05 equiv) and degassed 
with N2. The reaction was heated to 110 ⁰C and monitored by TLC for completion 
(approx 2hrs). The reaction was cooled, acidified (pH=3) with 2M HCl, filtered through 
Celite®, which was subsequently washed with EtOAc (10 mL/mmol). The filtrate was 
extracted with EtOAc (15 mL/mmol) and the organic phase was washed with brine (5 
mL/mmol), dried (MgSO4), and concentrated in vacuo. The crude residue was purified 
via chromatography on silica to give the desired product. 
5-bromo-N-(2-bromo-4-nitrophenyl)-2-hydroxybenzamide (4). 
 
5-Bromo-2-hydroxybenzoic acid (53 mg, 0.24 mmol) and 2-bromo-4-nitroaniline (50 mg, 
0.23 mmol) were reacted according to general procedure A, yielding the desired product 
as a yellow solid (47 mg, 0.11 mmol, 49%). Rf 0.39 (3:2 Hexanes/EtOAc); M.p. 237-240 
ºC; IR (cm-1) 3090, 1643, 1607, 1540, 1509; 1H NMR (400 MHz, DMSO-d6) 7.06 (1H, d, 
J = 8.7 Hz, H3’), 7.66 (1H, dd, J = 2.7 and 8.7 Hz, H4’), 8.11 (1H, d, J = 2.7 Hz, H6’), 8.34 
(1H, dd, J = 2.6 and 9.2 Hz, H5), 8.56 (1H, d, J = 2.6 Hz, H3), 8.77 (1H, d, J = 9.2 Hz, 
H6), 11.22 (1H, s, OH), 12.53 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6) 111.6 (C-Ar), 
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113.0 (C-Ar), 120.0 (C-Ar), 120.3 (C-Ar), 121.5 (C-Ar), 124.6 (C-Ar), 128.4 (C-Ar), 133.5 
(C-Ar), 137.2 (C-Ar), 142.9 (C-Ar), 143.2 (C-Ar), 156.1 (C-Ar), 163.0 (C=O); MS (ES-) 
m/z  413.2 [M79Br79Br-H]-,  415.0 [M79Br81Br-H]-, 417.0 [M81Br81Br-H]-.  
5-chloro-N-(2-chlorophenyl)-2-hydroxybenzamide (5). 
 
2-Chloroaniline (82 µL, 0.78 mmol) and 5-Clorosalicylic acid (203 mg, 1.17 mmol) were 
reacted according to general procedure A, resulting in the desired product a white solid 
(45 mg, 0.17 mmol, 21%). Rf 0.31 (4:1 Hexanes/EtOAc); M.p. 187-190 ºC; IR (cm
-1) 
3214, 2359, 1652, 1596, 1544; 1H NMR (400 MHz, DMSO-d6) 7.08 (1H, d, J = 8.8 Hz, 
H3’), 7.21 (1H, ddd, J = 2.9, 8.8 and 8.8 Hz, H5), 7.41 (1H, ddd, J = 1.4, 8.4 and 8.4 Hz, 
H4), 7.52 (1H, dd, J = 2.9 and 8.8 Hz, H4’), 7.57 (1H, dd, J = 1.4 and 8.4 Hz, H6), 8.0 
(1H, d, J = 2.9, H6’), 8.40 (1H, dd, J = 1.4 and 8.4, H3), 10.89 (1H, s, OH), 12.26 (1H, s, 
NH); 13C NMR (100 MHz, DMSO-d6) 119.6 (C-Ar), 120.1 (C-Ar), 123.4 (C-Ar), 124.0 (C-
Ar), 124.1 (C-Ar), 126.0 (C-Ar), 128.4 (C-Ar), 129.8 (C-Ar), 130.2 (C-Ar), 133.9 (C-Ar), 
135.5 (C-Ar), 155.9 (C-Ar), 163.2 (C=O); MS (ES-) m/z  280.2 [M35Cl35Cl-H]-,  282.2 




2-chloro-4-nitrophenyl 5-chloro-2-hydroxybenzoate (6). 
 
2-Chloro-4-nitrophenol (50 mg, 0.29 mmol) and 5-chlorosalicylic acid (65 mg, 0.38 
mmol) were reacted per general procedure A, yielding the desired product as a white 
solid which was determined to be a mixture of atrop isomers (26 mg, 0.077 mmol, 27%). 
Rf 0.32 (9:1 Hexanes/EtOAc); M.p. 165-168 ºC; IR (cm
-1) 3329, 3105, 1732, 1575, 1540; 
1H NMR (400 MHz, DMSO-d6) 6.89 (1.2H, d, J = 9.2 Hz, H
3’
major), 7.12 (1H, d, J = 9.2 
Hz, H3’minor ), 7.39 (1.2H, d, J = 8.7 Hz, H
6
major ), 7.64 (1H, dd, J = 2.8 and 9.2 Hz, 




major), 7.97 (2.2H, d, J = 2.8 Hz, H
6’
major and 
minor), 8.12 (1.2H, dd, J = 2.8 and 9.2 Hz, H
4’
major), 8.35 (1H, dd J = 2.8 and 9.0 Hz, 
H5minor), 8.46 (1.2H, d, J = 2.7 Hz, H
3
major), 8.54 (1H, d, J = 2.7 Hz, H
3
minor), 10.66 (1H, s, 
OHminor), 13.46 (1.2H, s, OHmajor); 
13C NMR (100 MHz, DMSO-d6) 115.2 (C-Ar), 116.6 
(C-Ar), 120.4 (C-Ar), 123.1 (C-Ar), 124.5 (C-Ar), 124.9 (C-Ar), 125.5 (C-Ar), 126.0 (C-
Ar), 126.1 (C-Ar), 126.4 (C-Ar), 126.7 (C-Ar), 127.8 (C-Ar), 130.9 (C-Ar), 132.0 (C-Ar), 
134.7 (C-Ar), 136.1 (C-Ar), 142.7 (C-Ar), 146.3 (C-Ar), 151.7 (C-Ar), 151.7 (C-Ar), 159.0 
(C-Ar), 159.3 (C-Ar), 162.4 (C=O), 164.7 (C=O) ; MS (ES-) m/z  326.2 [M35Cl35Cl-H]-,  






2-Chloroaniline (41 μL, 0.39 mmol) and 5-Chloro-2-methoxybenzoic acid (110 mg, 0.59 
mmol) were reacted according to general procedure A, resulting in a white solid (91 mg, 
0.31 mmol, 79%). Rf 0.52 (4:1 Hexanes/EtOAc); M.p. 148-151 ºC; IR (cm
-1) 3311, 3107, 
1699, 1587, 1522, 1541; 1H NMR (400 MHz, DMSO-d6) 4.08 (3H, s, OCH3) 7.20 (1H, 
ddd, J = 1.6, 7.7 and 8.0 Hz, H5) 7.35 (1H, d, J = 8.8 Hz, H3’), 7.40 (1H, ddd, J = 1.1, 
8.4, and 8.6 Hz, H4), 7.58 (1H, dd, J = 1.3 and 8.0 Hz, H6), 7.67 (1H, dd, J = 2.9 and 8.8 
Hz, H4’), 7.98 (1H, d, J = 2.9 Hz, H6’), 8.41 (1H, dd, J = 1.1 and 8.3 Hz, H3), 10.51 (1H, 
s, NH); 13C NMR (100 MHz, DMSO-d6) 57.6 (OCH3), 115.4 (C-Ar), 122.9 (C-Ar), 123.0 
(C-Ar), 123.7 (C-Ar), 125.6 (C-Ar), 125.8 (C-Ar), 128.4 (C-Ar), 129.8 (C-Ar), 130.9 (C-
Ar), 133.7 (C-Ar), 135.4 (C-Ar), 156.5 (C-Ar), 161.9 (C=O); MS (ES+) m/z  296.2 
[M35Cl35Cl+H]+,  298.0 [M35Cl37Cl+H]+, 300.0 [M37Cl37Cl+H]+.  




To a round bottom flask containing niclosamide (200mg, 0.61mmol), acetic anhydride 
(6mL) and a phosphoric acid (2 drops) were added. The reaction was stirred at 70 ⁰ C 
for approximately 1 hr. Addition of ice and water under cooling resulted in precipitate of 
product. Product was filtered and dried in a vacuum oven, giving a white solid (190 mg, 
0.51 mmol, 83%). Rf 0.59 (3:2 Hexanes/EtOAc); M.p. 175-178 ºC (lit. [173] 170 ºC); IR 
(cm-1) 3349, 3079, 1770, 1655, 1541, 1505; 1H NMR (400 MHz, DMSO-d6) 2.25 (3H, s, 
AcCH3), 7.36 (1H, d, J = 8.0 Hz, H
3’), 7.71 (1H, d, J = 8.6 Hz, H4’), 7.85 (1H, s, H6’), 8.09 
(1H, d, J = 10.0 Hz, H6), 8.27 (1H, d, J = 9.4 Hz, H5), 8.42 (1H, s, H3), 10.47 (1H, s, NH); 
13C NMR (100 MHz, DMSO-d6) 21.2 (C-Ac), 123.5 (C-Ar),  125.5 (C-Ar),  126.0 (C-Ar),  
126.5 (C-Ar),  127.7 (C-Ar),  129.6 (C-Ar),  130.2 (C-Ar),  130.5 (C-Ar),  132.5 (C-Ar),  
141.2 (C-Ar),  145.0 (C-Ar),  147.4 (C-Ar),  163.6 (C-Ar),  169.2 (C=O); MS (ES+) m/z  
386.2 [M35Cl35Cl+H+H2O]
+,  388.2 [M35Cl37Cl+H+H2O]
+, 390.4 [M37Cl37Cl+H+H2O]
+.  
4-chloro-2-((2-chloro-4-nitrophenyl)(methyl)carbamoyl)phenyl acetate (9). 
 
To an oven dried microwave vial K2CO3 (73 mg, 0.53 mmol), compound 8 (97 mg, 0.26 
mmol), and dimethylsulfate (13 µL, 0.13 mmol) were dissolved in dry acetone (~6mL) 
and heated at 60 ⁰C for 3.5 hrs. The resulting mixture was extracted in EtOAc (15mL) 
and water (10mL) to remove any remaining dimethylsulfate and the crude residue was 
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concentrated in vacuo. The crude residue was purified via flash chromatography (7:3 
Hexanes/EtOAc) to produce a viscous oil (52 mg, 0.13 mmol, 51%). Rf 0.29 (7:3 
Hexanes/EtOAc); 1H NMR (400 MHz, DMSO-d6) 2.23 (3H, s, AcCH3), 2.29 (3H, s, 
NCH3), 7.30 (1H, d, J = 8.0 Hz, H3’), 7.59 (1H, d, J = 9.0 Hz, H4’), 7.78 (1H, s, H6’), 7.97 
(1H, d, J = 8.7 Hz, H6), 8.33 (1H, d, J = 8.6 Hz, H5), 8.50 (1H, s, H3); 13C NMR (100 
MHz, DMSO-d6) 21.2 (C-Ac), 25.8 (NCH3), 124.0 (C-Ar),  125.7 (C-Ar),  125.9 (C-Ar),  
128.2 (C-Ar),  130.2 (C-Ar),  132.0 (C-Ar),  133.1 (C-Ar),  134.06 (C-Ar),  141.8 (C-Ar),  
146.2 (C-Ar),  148.6 (C-Ar),  166.5 (C-Ar),  167.0 (C-Ar),  171.6 (C=O); MS (ES+) m/z  
428.2 [M35Cl35Cl+H+H2O]





Compound 9 (36 mg, 0.095 mmol) was dissolved in MeOH (0.5 mL) and dioxane (1 mL) 
in a microwave vial. 2M NaOH (280 μL) was added and the reaction was stirred at room 
temperature for 2 hrs. Following completion, the reaction was brought to pH 2 using 2M 
HCl and extracted in EtOAc (15 mL). The organic layer was dried over MgSO4 and 
concentrated in vacuo to give a yellow solid (30 mg, 0.086 mmol, 91%). Rf 0.21 (7:3 
Hexanes/EtOAc); M.p. 218-222 ºC; IR (cm-1) 3249, 3099, 2921, 2852, 1771, 1675, 
1604, 1575, 1541; 1H NMR (400 MHz, DMSO-d6) 3.57 (3H, s, NCH3), 7.10 (1H, d, J = 
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8.8 Hz, H3’), 7.55 (1H, dd, J = 2.8 and 8.8 Hz, H4’), 7.98 (1H, d, J = 2.8 Hz, H6’), 8.31 
(1H, dd, J = 2.8 and 9.2 Hz, H5), 8.45 (1H, d, J = 2.8 Hz, H6), 8.83 (1H, d, J = 9.2 Hz, 
H3), 11.46 (1H, s, OH); 13C NMR (100 MHz, DMSO-d6) 66.8 (NCH3), 119.7 (C-Ar),  
119.9 (C-Ar),  121.2 (C-Ar),  122.8 (C-Ar),  124.1 (C-Ar),  124.3 (C-Ar),  125.2 (C-Ar),  
130.5 (C-Ar),  134.4 (C-Ar),  141.7 (C-Ar),  143.0 (C-Ar),  155.8 (C-Ar),  163.1 (C=O); 
MS (ES-) m/z  325.0 [M35Cl35Cl-H+H2O]






2-Chloro-4-nitroaniline (200 mg, 1.2 mmol) and 5-nitrosalicylic acid (320 mg, 1.7 mmol) 
were reacted using general procedure A, yielding the desired compound as a yellow 
solid (240 mg, 0.72 mmol, 62%). Rf 0.32 (17:3 DCM/MeOH); M.p. 270-273 ºC; IR (cm
-1) 
3184, 3077, 1696, 1586, 1559, 1515; 1H NMR (400 MHz, DMSO-d6) 6.59 (1H, d, J = 9.4 
Hz, H6), 8.00 (1H, dd, J = 3.3 and 9.4 Hz, H5), 8.26 (1H, dd, J = 2.8 and 9.3 Hz, H4’), 
8.38 (1H, d, J = 2.8 Hz, H6’), 8.77 (1H, d, J = 3.3 Hz, H3), 8.93 (1H, d, J = 9.3 Hz, H3’), 
11.62 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6) 118.8 (C-Ar),  119.1 (C-Ar),  121.4 
(C-Ar),  123.1 (C-Ar),  124.3 (C-Ar),  125.2 (C-Ar),  127.9 (C-Ar),  129.7 (C-Ar),  139.9 
(C-Ar),  141.5 (C-Ar),  143.1 (C-Ar); MS (ES-) m/z 336.2 [M35Cl-H]-, 338.2 [M37Cl-H]-. 
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*NOTE: unable to visualize all carbons 
5-amino-N-(4-amino-2-chlorophenyl)-2-hydroxybenzamide (12). 
 
Compound 11 (50 mg, 0.15 mmol) was reacted with tin(II) chloride (110 mg, 0.60 mmol) 
using general procedure B, resulting in a yellow-orange solid (14 mg, 0.05 mmol, 34%). 
Rf 0.39 (9:1 DCM/MeOH); M.p. 227-230 ºC; IR (cm
-1) 3366, 2922, 2359, 1716, 1652, 
1540;  1H NMR (400 MHz, DMSO-d6) 4.75 (2H, s, NH2), 5.28 (2H, s, NH’2), 6.55 (1H, d, 
J = 8.7 Hz, H3’), 6.68-6.73 (3H, m, H5, H6, and H4’), 7.24 (1H, m, H3), 7.79 (1H, d, J = 8.7 
Hz, H6’), 10.43 (1H, s, OH), 10.82 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6) 113.3 (C-
Ar),  113.9 (C-Ar),  114.7 (C-Ar),  117.9 (C-Ar),  118.4 (C-Ar),  120.6 (C-Ar),  124.2 (C-
Ar),  125.8 (C-Ar),  126.1 (C-Ar),  141.7 (C-Ar),  147.3 (C-Ar),  148.4 (C-Ar),  165.1 







Niclosamide (50 mg, 0.15 mmol) was reacted with tin(II) chloride (120 mg, 0.61 mmol) 
using general procedure B, resulting in a brown solid (56 mg, 0.15 mmol, 96%). Rf 0.36 
(3:2 Hexanes/EtOAc); M.p. 187-190 ºC (lit.[174] 196-197 ºC); IR (cm-1) 3355, 3279, 
2359, 1652, 1600, 1556; 1H NMR (400 MHz, DMSO-d6) 5.38 (2H, s, NH2), 6.56 (1H, d, J 
= 8.8 Hz, H5), 6.72 (1H, s, H3), 7.03 (1H, d, J = 8.8 Hz, H6), 7.48 (1H, d, J = 8.9 Hz, H4’), 
7.66 (1H, d, J = 8.8 Hz, H3’) 8.02 (1H, s, H6’) 10.39 (1H, s, OH) 12.24 (1H, s, NH); 13C 
NMR (100 MHz, DMSO-d6) 113.3 (C-Ar),  113.9 (C-Ar),  119.2 (C-Ar),  119.6 (C-Ar),  
123.1 (C-Ar),  123.5 (C-Ar),  126.7 (C-Ar),  127.2 (C-Ar),  129.3 (C-Ar),  133.6 (C-Ar),  
148.1 (C-Ar),  157.0 (C-Ar),  164.3 (C=O); MS (ES+) m/z  297.0 [M35Cl35Cl+H]+,  299.0 
[M35Cl37Cl+H]+, 301.2 [M37Cl37Cl+H]+. 




5-chloro-4-iodo-2-methoxybenzoic acid (200 mg, 0.64 mmol) and benzene boronic acid 
(94 mg, 0.77 mmol) were reacted according to general procedure C, yielding the 
desired product, a pale yellow solid (130 mg, 0.49 mmol, 76%). Rf 0.24 (3:7 
Hexanes/EtOAc); M.p. 143-146 ºC; IR (cm-1) 2925, 2847, 2357, 1698, 1674, 1653, 
1541; 1H NMR (400 MHz, DMSO-d6) 3.87 (3H, s, OCH3), 7.12 (1H, s, H
6), 7.47-7.50 
(5H, m, phenyl), 7.76 (1H, s, H3), 12.98 (1H, s, COOH); 13C NMR (100 MHz, DMSO-d6) 
56.7 (OCH3), 116.1 (C-Ar), 122.2 (C-Ar), 122.4 (C-Ar), 128.7 (C-Ar), 129.6 (C-Ar), 131.9 




*NOTE: unable to visualize all carbons 
2-chloro-5-hydroxy-[1,1'-biphenyl]-4-carboxylic acid (15). 
 
To a mixture of compound 14 (88 mg, 0.34 mmol) in DCM at -78 ºC was added BBr3 
(1.0 mL, 1.0 mmol of 1M solution in DCM), and the reaction was allowed to warm to 
room temperature and stirred for 1.5hrs.  The reaction was brought to pH 2 using 2M 
HCl and then extracted in EtOAc (20mL) and water (10 mL), dried over MgSO4 and 
concentrated in vacuo resulting in a white solid (81 mg, 0.33 mmol, 97%). Rf 0.13 (9:1 
DCM/MeOH); M.p. 167-170 ºC; IR (cm-1) 3292, 2852, 2548, 1667, 1616; 1H NMR (400 
MHz, DMSO-d6) 7.00 (1H, s, H
6), 7.46-7.49 (5H, m, phenyl), 7.87 (1H, s, H3), 11.30 (1H, 
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s, COOH), 16.47 (1H, s, hydroxyl); 13C NMR (100 MHz, DMSO-d6) 114.3 (C-Ar), 120.3 
(C-Ar), 121.6 (C-Ar), 128.8 (C-Ar), 128.9 (C-Ar), 129.4 (C-Ar), 131.2 (C-Ar), 138.2 (C-
Ar), 146.8 (C-Ar), 159.8 (C-Ar), 170.8 (COOH); MS (ES-) m/z 247.2 [M35Cl-H]-, 249.0 
[M37Cl-H]-. 
*NOTE: unable to visualize all carbons 
2-chloro-N-(2-chloro-4-nitrophenyl)-5-hydroxy-[1,1'-biphenyl]-4-carboxamide (16). 
 
Compound 15 (69 mg, 0.28 mmol) and 2-Chloro-4-nitroaniline (37 mg, 0.21 mmol) were 
reacted according to procedure A, resulting in the desired product, a yellow solid (16 
mg, 0.040 mmol, 19%). Rf 0.28 (7:3 Hexanes/EtOAc); M.p. 230-232 ºC; IR (cm
-1) 3281, 
3079, 2924, 2852, 2358, 1631, 1541, 1508; 1H NMR (400 MHz, DMSO-d6) 7.05 (1H, s, 
H3’), 7.44-7.53 (5H, m, phenyl), 8.07 (1H, s, H6’), 8.29 (1H, dd, J = 2.6 and 9.2 Hz, H5), 
8.41 (1H, d, J = 2.6 Hz, H6), 8.83 (1H, d, J = 9.2 Hz, H3), 11.30 (1H, s, OH), 12.69 (1H, 
s, NH); 13C NMR (100 MHz, DMSO-d6) 118.9 (C-Ar), 120.2 (C-Ar), 121.0 (C-Ar), 122.7 
(C-Ar), 122.8 (C-Ar), 124.3 (C-Ar), 125.2 (C-Ar), 128.8 (C-Ar), 128.9 (C-Ar), 129.3 (C-
Ar), 132.1 (C-Ar), 138.1 (C-Ar), 141.6 (C-Ar), 142.9 (C-Ar), 145.5 (C-Ar), 155.3 (C-Ar), 
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162.7 (C=O); MS (ES-) m/z  401.2 [M35Cl35Cl-H]-,  403.2 [M35Cl37Cl-H]-, 405.2 
[M37Cl37Cl-H]-. 
*NOTE: unable to visualize all carbons 
5-chloro-4-(furan-2-yl)-2-methoxybenzoic acid (17). 
 
5-Chloro-4-iodo-2-methoxybenzoic acid (250 mg, 0.80 mmol) and furan-2-boronic acid 
(270 mg, 2.4 mmol) were reacted per general procedure C, apart from 3 equiv of 
boronic acid, yielding the desired product a tan solid (61 mg, 0.72 mmol, 30%). Rf 0.29 
(3:7 Hexanes/EtOAc); M.p. 148-152 ºC; IR (cm-1) 3079, 2924, 2848, 2344, 1699, 1600, 
1541; 1H NMR (400 MHz, DMSO-d6) 3.91 (3H, s, OCH3), 6.73-6.74 (1H, m, furan-H
4), 
7.32 (1H, m, furan-H5), 7.48 (1H, s, H3), 7.77 (1H, m, furan-H3), 7.94 (1H, s, H6), 12.96 
(1H, s, COOH); 13C NMR (100 MHz, DMSO-d6) 56.6 (OCH3), 111.4 (C-Ar), 112.9 (C-Ar), 
113.3 (C-Ar), 119.9 (C-Ar), 121.4 (C-Ar), 129.2 (C-Ar), 129.3 (C-Ar), 131.9 (C-Ar), 132.0 
(C-Ar), 133.2 (C-Ar), 144.7 (C-Ar), 149.0 (C-Ar), 157.5 (C-Ar), 166.0 (COOH); MS (ES+) 




5-chloro-4-(furan-2-yl)-2-hydroxybenzoic acid (18). 
 
To a mixture of compound 17 (100 mg, 0.40 mmol) in DCM at -78 ºC was added BBr3 
(1.2 mL, 1.2 mmol of 1M solution in DCM), and the reaction was stirred at room 
temperature for 1.5hrs.  The reaction was brought to pH 2 using 2M HCl and then 
extracted in EtOAc (15mL) and water (10mL), dried over MgSO4 and concentrated in 
vacuo resulting in a tan solid (95 mg, 0.39 mmol, 99%). Rf 0.11 (9:1 DCM/MeOH); M.p. 
184-187 ºC; IR (cm-1) 2921, 2341, 1683, 1558; 1H NMR (400 MHz, DMSO-d6) 6.69-6.70 
(0.6H, m, furan-H4minor), 6.72-6.73 (1H, m, furan-H
4
major), 7.29-7.29 (1.2H, m, H
3
minor and 
furan-H5minor), 7.34-7.35 (1H, m, furan-H
5
major), 7.38 (1H, s, H
3
major), 7.80 (0.6H, s, 
H6minor), 7.85 (1H, s, H
6
major), 7.90-7.90 (0.6H, m, furan-H
3
minor), 7.93-7.93 (1H, m, furan-
H3major);
 13C NMR (100 MHz, DMSO-d6) 112.7 (C-Ar), 113.0 (C-Ar), 115.3 (C-Ar), 116.7 
(C-Ar), 117.8 (C-Ar), 132.3 (C-Ar), 133.1 (C-Ar), 144.5 (C-Ar), 149.2 (C-Ar), 160.5 (C-






Compound 18 (72 mg, 0.30 mmol) and 2-chloro-4-nitroaniline (40 mg, 0.23 mmol) were 
reacted according to general procedure A to achieve the final compound, a yellow solid 
(38 mg, 0.097 mmol, 42%). Rf 0.27 (7:3 Hexanes/EtOAc); M.p. 245-248 ºC; IR (cm
-1) 
3091, 2357, 1636, 1596, 1541; 1H NMR (400 MHz, DMSO-d6) 6.72-6.73 (1H, m, furan-
H4), 7.34 (1H, m, furan-H5), 7.55 (1H, s, H3’), 7.95 (1H, s, H6’), 8.06 (1H, m, furan-H3), 
8.28-8.30 (1H, m, H6), 8.43-8.43 (1H, m, H5), 8.82-8.84 (1H, m, H3), 11.28 (1H, s, OH) 
12.65 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6) 113.0 (C-Ar), 113.8 (C-Ar), 115.4 (C-
Ar), 118.3 (C-Ar), 119.9 (C-Ar), 121.0 (C-Ar), 122.7 (C-Ar), 124.3 (C-Ar), 125.2 (C-Ar), 
133.2 (C-Ar), 133.3 (C-Ar), 141.6 (C-Ar), 142.9 (C-Ar), 145.0 (C-Ar), 148.5 (C-Ar), 155.4 







2-Chloro-4-nitroaniline (50 mg, 0.29 mmol) and dichlorobenzoic acid (83 mg, 0.44 
mmol) were reacted according to general procedure A, resulting in the desired 
compound a pale yellow solid (63 mg, 0.18 mmol, 63%). Rf 0.53 (4:1 Hexanes/EtOAc); 
M.p. 197-200 ºC; IR (cm-1) 3230, 3094, 2357, 1668, 1507; 1H NMR (400 MHz, DMSO-
d6) 7.63-7.63 (2H, m, H
3’ and H4’), 7.80-7.80 (1H, m, H6), 8.18-8.20 (1H, m, H6’), 8.29-
8.31 (1H, m, H5), 8.41 (1H, m, H3), 10.72 (1H, s, NH); 13C NMR (100 MHz, DMSO-d6) 
123.5 (C-Ar), 125.5 (C-Ar), 126.4 (C-Ar), 127.4 (C-Ar), 129.4 (C-Ar), 131.8 (C-Ar), 131.9 
(C-Ar), 132.3 (C-Ar), 137.7 (C-Ar), 140.9 (C-Ar), 145.0 (C-Ar), 164.7 (C=O); MS (ES+) 
m/z  343.0 [M35Cl35Cl35Cl+H]+,  345.0 [M35Cl35Cl37Cl+H]+, 347.2 [M35Cl37Cl37Cl+H]+, 
349.0 [M37Cl37Cl37Cl +H]+. 
FP assay 
FP assay was conducted as previously reported [85, 86, 144]. Briefly, assay 
buffer (10 mM HEPES, pH 7.5, 50 mM NaCl, 1 mM EDTA, 2 mM DTT, and 0.01% 
Triton-X100), 100 nM of full length GST-tagged human STAT3 protein (Abcam), and 
varying concentrations of compounds were incubated for 1 hour at room temperature 
with mild agitation in 96-well half area black plates (Corning). Fluorescent peptide 5-
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FAM-G(pTyr)LPQTV-CONH2 (Genscript) was added to each assay well at a 
concentration of 10 nM. Final well volumes were 30 µL. Following incubation with 
fluorescent peptide for 30 minutes at room temperature with mild agitation, plates were 
examined using FP Fluorescein Dual module with excitation filter FITC FP 480 and 
emission filter FITC FP P-pol535 and S-pol535. Data was expressed as percent control 
using the equation %C = (mPdrug-mPfree)/(mPSTAT3-mPfree)*100 where mP is the value for 
FP measurement. 
Recombinant STAT3 ELISA 
Measurement of STAT3 binding to DNA was performed using a TransAM STAT3 
ELISA kit (Active Motif) and according to the previously used protocol [144]. Briefly, full-
length, GST-tagged human STAT3 protein and various concentrations of compounds to 
be evaluated or niclosamide were incubated in Complete Lysis Buffer at a final volume 
of 20 µL containing 0.1 μg recombinant protein for 1 hour with mild agitation. Following 
incubation with STAT3 inhibitors, samples were added to corresponding ELISA wells 
with 30 µL of Complete Binding Buffer and inhibition of STAT3 protein binding to the 
DNA consensus sequence was determined. Data was reported as percent of control. 
MTT assay 
HeLa cells were plated in 96-well plates at a density of 5,000 cells/well in 100 μL 
of media and were incubated for 24 hours. Media was then aspirated and replaced with 
100 μL of media containing various concentrations of compounds ranging from 500 μM-
0.0019 µM. Cells were exposed to compounds for 24 hours, following which the media 
was aspirated and 50 μL MTT solution diluted in media was added to each well at a final 
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concentration of 1 mg/mL. MTT was exposed to cells for 4 hours, aspirated, and then 
100 μL of DMSO was added to each well. Plates were agitated for 10 minutes prior to 
reading absorbance at 540nm in a microplate reader. Data was normalized and 
reported as percent of control. 
Nuclear extract preparation 
Nuclear extracts were prepared using a nuclear extraction kit (Signosis) 
according to product directions. Briefly, 100mm dishes of cells were washed with 1X 
PBS and then 1mL of 1X Buffer I was added and dishes were rocked on ice for 10 
minutes. Cells were released from the dish using a sterile scraper and centrifuged at 
1200rpm for 5 minutes at 4⁰C. The supernatant was discarded and the pellets were 
resuspended in 1X Buffer II and shaken on ice for 2 hours. Samples were centrifuged at 
1200rpm for 5 minutes at 4⁰C and the resulting supernatants containing the nuclear 
extracts were placed in new microcentrifuge tubes. Protein concentrations of samples 
were determined via Bradford assay. 
Cell-based STAT3 DNA-binding ELISA  
HeLa cells were plated at 1 million cells per 100mm dish and incubated for 
approximately 72 hours, resulting in serum-starved confluent plates. Plates were then 
washed with PBS and fresh media was added containing concentrations of compounds 
to be evaluated or niclosamide for 24 hours. For single concentrations of compounds, 
cells were treated with 1 µM of compounds, as derived from 24 hour MTT assay EC50 
value for niclosamide. Dose-responses of niclosamide, compound 10, and compound 
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19 were similarly prepared at concentrations ranging from 2–0.0156 µM. Following 
incubation with compounds, cellular nuclear extracts were prepared.  
Measurement of STAT3 binding to DNA was performed using the TransAM 
STAT3 ELISA kit. Sample wells contained 20 µg of nuclear extracts from treated HeLa 
cells diluted in 20 µL of Complete Lysis Buffer. The ELISA was then performed as 
described in the recombinant ELISA section. Data was normalized and reported as 
percent of control. 
Caspase 3/7 assay 
 The effect of STAT3 inhibitor, cisplatin, or combination therapy on caspase 
activity was evaluated using a Caspase-Glo 3/7 kit (Promega) according to product 
directions. Briefly, HeLa cells were plated in white-walled, clear bottom 96-well plates at 
a density of 5,000 cells/well in 100 μL of media and were incubated for 24 hours. Media 
was then aspirated and replaced with 100 μL of media containing 1 µM or 10 µM of 
STAT3 inhibitor with or without 20 µM of cisplatin. Cisplatin was also treated as a single 
agent at 20 µM. Cells were exposed to compounds for 24 and 48 hours, following which 
plates were allowed to equilibrate to room temperature. Reconstituted caspase reagent 
was added to sample wells in a 1:1 ratio, mixed, and incubated in the dark for 1 hour. 
Luminescence was read using a microplate reader. 
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.0. Data for IC50 and 
EC50 curves was normalized. Error bars represent the standard error of the mean 
(SEM). Analysis by one-way analysis of variance (ANOVA) was conducted with Tukey's 
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multiple comparison post hoc test. Statistical significance was set at P < 0.05. 
Experiments were repeated in triplicate.  
Results 
Rational design of niclosamide analogs through in silico design 
The SiteMap function in Maestro identified both the previously reported DNA-
binding site [175], and the site identified in chapter 2. Niclosamide and the OTAVA 
fragment library were docked into both sites and fragments were overlaid on 
niclosamide to identify potentially favorable modifications. Additional modifications were 
proposed that were expected to be unfavorable for binding based on disruption of 
interactions of niclosamide with surrounding amino acid residues. Both favorable and 
unfavorable compound structures were proposed for each site in an attempt to elucidate 
binding location of inhibitors. 
A total of 10 designed analogs of niclosamide were successfully synthesized for 
in vitro testing (Figure 4.1). These analogs were then docked into both potential binding 
sites and ranked by XP Gscore with the most negative scores being the most favorable 
(Table 4.1). Compound 19 was the most favorable for the DBD and 11 was the most 
favorable for the LD with XP Gscores of -6.986 and -4.685 respectively. Two additional 
compounds were later included in the batch although not originally designed. 
Compound 8, although an intermediate, as well as 20, were synthesized to replace 
originally designed compounds that aimed to disrupt the H-bonding potential of the 




Figure 4.1:Structures of synthesized niclosamide analogs 
Computational screen identified small molecules with ≥85% similarity to niclosamide 
To identify commercially available compounds with potential inhibitory activity 
against STAT3 we utilized the computational modeling suite Cresset Forge. Small 
molecules bind to protein targets based primarily on 3D shape and electronic properties 
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(charge, hydrophobicity, etc.), also referred to as the molecular force field. By 
comparing the fields among a series of compounds, we can identify structurally diverse 
compounds with potentially similar biological activities, even in the absence of a known 
protein target. Within Forge, we calculated, aligned, and compared the molecular force 
fields of each of the ~1600 compounds in the NIH Diversity III library using our 
niclosamide docking results in either the DBD or the linker domain as the reference 
(Figure 4.2). Interestingly, although there were some predicted differences in binding 
orientation of niclosamide between the two sites, the top scoring compound was 
identical (Figure 4.3). Several compounds were identified as top hits in both sites. 
These include 36815, 164464, and 176736 (Figure 4.4). All of the compounds were 
requested from the chemical repository within the Developmental Therapeutics Program 
at NCI. Preparation of stock solutions in DMSO revealed insolubility issues with 
compound 294747, and it was excluded from being tested in vitro. The remaining 17 
compounds were evaluated for their affinity for recombinant STAT3. 
Table 4.1: Docking scores of synthesized analogs 
Compound DBD XP Gscore LD XP Gscore 
19 -6.986 -3.274 
13 -6.33 -3.057 
niclosamide -6.037 -4.589 
4 -5.91 -3.396 
11 -5.871 -4.685 
12 -5.687 -3.932 
16 -5.669 -2.762 
7 -5.23 -2.869 
6 -5.126 -3.879 
5 -4.768 -4.363 





Figure 4.2: Niclosamide docked in two binding sites on STAT3 near DNA. 
 
Niclosamide and similar compounds do not target the SH2 domain of STAT3 to varying 
degrees 
NCI compounds and synthesized niclosamide analogs were evaluated for their 
affinity for the SH2 domain of STAT3 using an FP assay. Niclosamide was included as 




Figure 4.3:Cresset Forge identifies compounds similar to niclosamide. A) Overlay in 
linker domain of niclosamide and top hit, B) niclosamide in linker domain with 
interactions displayed as polyhedrons, and C) NCI compound 343557 (12) in linker 
domain with interactions displayed as spheres. Interactions include positive (red), 




Figure 4.4: Compounds identified from a computational screen against niclosamide 




At a single high concentration of 25 µM, no compounds reduced binding of the 
fluorescent peptide by 50% (Figure 4.5). Compounds 29, 31, 37, and analogs 4, 12, 
and 16 demonstrated slight affinity for the SH2 domain. Analysis by one-way ANOVA 
determined there was no significant difference between niclosamide and its structurally 
similar counterparts. Since all compounds had little to no affinity for the SH2 domain of 
STAT3 at high concentrations, they were then evaluated for their DBD inhibitory 
potential. 
 
Figure 4.5: FP assay measures affinity for STAT3 SH2 domain. Compounds A) 
synthesized analogs and B) NCI compounds were evaluated for their ability to disrupt 
fluorescent peptide binding at 25µM in the FP assay. 
 
A recombinant ELISA identifies compounds that target the DNA-binding domain of 
STAT3 
 Using the workflow outlined in chapter 3, compounds were next evaluated in a 
recombinant ELISA to determine their effects on STAT3/DNA binding. As the purpose of 
this study is to identify compounds that are structurally similar to niclosamide, but have 
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equal or better potency for STAT3, compounds were tested at the recombinant IC50 of 
niclosamide in this assay (2 µM). Niclosamide was also included for validation. At a 
concentration of 2 µM, all of the compounds evaluated reduced recombinant 
STAT3/DNA-binding. Analysis by one-way ANOVA determined there was a statistically 
significant difference of the means (F(31,143)=3.461, P<0.0001), and a post hoc Tukey 
test revealed that compounds 5 and 6 were less potent than niclosamide with statistical 
significance (P<0.05).  Compounds selected for further investigation in vitro were NCI 
compounds 23-27, 32-34, and synthesized analogs 10, 11, 19, and 20. 
 
Figure 4.6: Recombinant ELISA identifies compounds that target the DNA-binding 
domain of STAT3. Recombinant STAT3 protein was incubated for 1 hour with 2 µM of 
A) synthesized analogs or B) NCI compounds prior to evaluation by ELISA. ** P=0.001, 
*** P<0.0001 
 
19 and 10 inhibit STAT3-DNA binding and induce apoptosis in cells 
 Compounds selected for investigation in cells were first assessed for their impact 
on cell viability via MTT in order to determine if any single compound had an EC50 lower 
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than niclosamide. 10 and 19 were calculated to have EC50s of 1.146 ± 0.38 µM and 
0.3154 ± 0.07 µM respectively (Figure 4.7A). Confluent plates of HeLa cells were then 
treated with 1µM of compounds for 24 hours prior to preparation of nuclear extracts. In a 
cell-based ELISA, niclosamide, 10, and 19 reduced STAT3/DNA-binding by ~80% at 
concentrations of 1µM (Figure 4.7C). A dose-response curve for each of the three 
compounds determined the following EC50 values: niclosamide 0.179± 0.028 µM, 10 
0.239 ± 0.039 µM and 19 0.059 ± 0.011 µM (Figure 4.7D).  
 HeLa cells were then treated with 10, 19, or niclosamide as single agents or in 
combination with 20 µM cisplatin at concentrations of 1 and 10 µM for 24 and 48 hours. 
As single agent treatments, 10 µM 10 and 1 µM SF24 displayed a time-dependent 
increase in apoptosis (Figure 4.7E and 4.7F). Niclosamide at 1 µM demonstrated only 
a slight increase in apoptosis compared to untreated control at both 24 and 48 hours. At 
10 µM, niclosamide induced twice as much apoptosis compared to untreated control 
and this response was the similar at 24 and 48 hours (Figure 4.7E and 4.7F). 
Combination therapy with 20 µM cisplatin only slightly increased apoptosis compared to 
single agent therapies at both time points; however, cisplatin had the greatest impact on 




Figure 4.7: Compounds 10 and 19 potently inhibit the DBD of STAT3. HeLa cells were 
treated with A) synthesized analogs or B) NCI compounds for 24h were assessed for 
cell viability by MTT. C) Cell-based ELISA of HeLa cells dosed for 24h with 1 µM of 
compounds. D) Dose-response of HeLa cells treated with niclosamide, 10 or 19 for 24h. 
Measurement of induction of apoptosis after E) 24h and F) 48h treatment of 




We have identified two potential binding sites within STAT3 that have the 
potential for small molecule targeting and ultimately abrogate the activity of STAT3 as a 
transcription factor. However, both sites contain amino acid residues that have been 
demonstrated to interact with the targeted DNA consensus sequence [142]. Therefore, 
we used small molecules as chemical probes to try and elucidate which site was 
preferred for inhibiting STAT3/DNA-binding. To maximize compound diversity, we 
examined both a commercially available compound library as well as a fragment library 
to identify structural analogs of niclosamide. From the output of the fragment 
computational docking, we observed a preference for 5-, and 6-membered rings within 
the upper DNA binding region. This prompted the design of compounds 16 and 19. The 
binding site located in the linker domain was larger and may require compounds 
capable of making key interactions with residues within the target binding site, while 
also extending out of the pocket to sterically hinder interactions with DNA.  
The initial structural modifications were minor, such as replacing the chlorine 
atoms with larger bromine atoms. Within the linker domain binding site, the nitro-group 
on niclosamide appeared to make more residue interactions, while in the DNA binding 
domain site the nitro-group was exposed to solvent and not contained within the binding 
site. Compounds 5 and 7 contained no nitro-group and compounds 12 and 13 replaced 
the nitro-group with an electron-donating amine. Potential hydrogen bonding 
interactions were addressed through the methylation or acetylation of the hydroxyl 
group in compounds 7 and 8, while compound 20 replaced the hydroxyl group with a 
chlorine atom. Similarly, methylation of the amide nitrogen in compound 10 attempted to 
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disrupt favorable hydrogen-bonding interactions, and 6 substituted the amide for an 
ester. 
Docking the designed analogs in both sites revealed higher XP Gscores for the 
target site within the DNA-binding domain compared to the site in the linker domain. 
This may be due to the tertiary structure of the DNA-binding domain with its fluid loops, 
which may allow for greater flexibility for compound interactions. In the DNA-binding 
domain 19 had the highest ranking, and in the linker domain 11 had the most favorable 
scores. Once the computational modeling and in silico design was completed we 
synthesized the proposed analogs of niclosamide. Several synthesis methods were 
attempted before final amide linking conditions were optimized. We determined that 
microwave irradiation was necessary to overcome the activation energy required for 
amide formation, while also effectively reducing the time needed for reaction 
completion. Isolation of several compounds also proved to be difficult due to the co-
elution of the aniline starting material with the final product. At completion, we 
successfully synthesized 12 analogs of niclosamide to test in vitro. 
We also employed the Cresset modeling software Forge to identify a more 
diverse set of analogs to test in vitro. This software used the docked conformations of 
niclosamide in the two binding sites to identify similar compounds from the NCI Diversity 
III library. This program is interesting in that it first overlays the compound library and 
the lead compound to recognize similarities based on structure and charge. Then, the 
top hits are docked into the target binding sites and ranked on binding potential. The 
final output gives a 4-point similarity plot and an overall percent similarity based on both 
structural and docking potentials. A total of 18 compounds were identified as having 
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85% or better similarity to niclosamide in one or both binding sites. Nearly all of the 
compounds contained two aromatic rings linked by an amide, and the top hit for both 
sites was the same compound. 
With 30 compounds identified, we followed the tandem screening approach 
proposed in chapter 3 to evaluate their impact as STAT3 inhibitors in vitro. In the FP 
assay, none of the compounds reduced fluorescent peptide binding below 50%. SH2 
domain STAT3 inhibitors such as S3I-1757 and A26 displayed complete inhibition of 
fluorescent peptide binding at concentrations above 10 µM [144], and little to no activity 
at a concentration of 25 µM, suggests that these compounds do not inhibit STAT3 at its 
SH2 domain. Niclosamide was also evaluated in conjunction with the NCI compounds 
and its synthesized analogs, and showed no activity in the FP assay at 25 µM. Negative 
results in the FP assay excludes the SH2 domain, and compounds were next evaluated 
in a recombinant STAT3 ELISA. 
In the previous chapter we determined the IC50 of niclosamide in the recombinant 
ELISA to be 1.93 ± 0.70 μM [144]. In order to identify compounds with activity greater 
than or equal to niclosamide, we evaluated the similar compounds at a single 
concentration of 2 µM. In the recombinant ELISA, inhibition of STAT3/DNA-binding was 
approximately ±15% of the activity recorded for niclosamide. This is not a surprising 
result as we had chosen to test compounds within 85% similarity to our lead molecule. 
Analysis by one-way ANOVA determined a P value < 0.0001, however the Tukey post 
hoc test revealed that only 5 and 6 were statistically different from niclosamide. Both of 
these compounds performed worse than niclosamide in the recombinant ELISA with 
means of 80% and 76% of STAT3 only control, respectively. Taking this into account, 
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we chose NCI compounds 23-27 and 32-34 as well as synthesized analogs 10, 11, 19, 
and 20 to evaluate in cells. It is worth noting that from our computational modeling the 
top hits from both sites (19, 11, and 22) were chosen for further investigation. 
The impact of the 12 compounds on cell viability after 24-hour treatment was 
assessed by MTT. Unlike our previous methods, the purpose of the MTT in this study 
was to determine if any single compound had a greater impact on cell viability 
compared to niclosamide. As previously discussed, treatment of cells for evaluation in a 
cell-based ELISA is limited to concentrations at or below the EC50 in order to preserve 
cell quantity required to produce 20 µg of nuclear extract protein. Our intention was to 
assess these compounds in cells at the EC50 for niclosamide; therefore, we first needed 
to determine if any compound had an EC50 below 1 µM. Although 19 had a calculated 
EC50 of 0.3154 ± 0.07 µM, total cell viability did not drop below 50% until high 
concentrations. Thus, we concluded that we could examine STAT3/DNA-binding 
inhibition in cells following a single 24-hour treatment at 1 µM. 
In the cell-based ELISA niclosamide, 10, and 19 significantly reduced 
STAT3/DNA-binding by approximately 80%. A dose-response for 10 and 19 was 
generated and EC50s were calculated to be 0.239 µM and 0.059 µM respectively. 
Compared with the EC50 of 0.180 µM for niclosamide, 10 was concluded to be slightly 
less potent than niclosamide, while 19 was more than twice as potent as our lead. 
Looking at the computational modeling, this potency may suggest the DNA-binding 
domain site as the target site over the linker domain based on binding orientations of 
the two compounds compared to niclosamide (Figure 4.8). 10 does not appear to have 
a favorable binding position within the DBD, while it appears to bind linearly in the LD 
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site. In contrast, 19 appears to have favorable binding positions in both sites. While it is 
optimistic to believe that 19 targets only one binding site within the DNA-binding region 
of STAT3, it is also possible that it binds in both sites favorably and induces a greater 
conformational change of the protein to inhibit DNA interactions. Without x-ray 
crystallography for confirmation, the only conclusion that can be made is that 19 
potently inhibits STAT3/DNA-binding. 
 
Figure 4.8: Docking of 10 and 19 in both sites. Overlay of niclosamide and A) 19 and B) 
10 in the DBD binding site with DNA bound. Overlay of niclosamide and C) 19 and D) 
10 in the LD binding site and its relation to DNA. 
 
 Once it had been determined that 10 and 19 potently inhibit STAT3/DNA-binding, 
we examined the potential of these compounds to induce apoptosis in cells. 
Constitutively active STAT3 can drive anti-apoptosis, and induction of apoptosis is a 
downstream marker of apoptosis [2, 15, 34]. Following 24 hour treatment, 10µM 
niclosamide and 10µM 19 as single agents induced a 2-fold increase in apoptosis. 10 
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did not induce a similar response until 48 hours treatment. In combination with cisplatin, 
all three compounds demonstrated an increase in apoptosis compared to their response 
as a single agent. However, at 24 hours treatment this response was not statically 
different from the response observed by cisplatin as a single agent. Following treatment 
for 48 hours as a single agent, cisplatin induced a 6-fold increase in apoptosis, but the 
combination therapies with the STAT3 inhibitors remained at or below a 3-fold increase 
in apoptosis. This response warrants further investigation, as there may be alternative 
cell survival mechanisms activated to compensate for STAT3 inhibition. 
 In conclusion, we have demonstrated that niclosamide, 10, and 19 inhibit 
STAT3/DNA-binding in vitro, and that 19 is a more potent inhibitor in cells than our lead. 
Further investigation on the binding orientation of 19 and STAT3 will need to be 
conducted in order to verify its target binding site on STAT3. Additionally, the impact of 
19 on downstream targets of STAT3 will need to be elucidated, although this work is 
beyond the scope of the present study. We have successfully identified a novel small 
molecule inhibitor of STAT3 that targets the DNA-binding domain of STAT3 and has 




SUMMARY AND FUTURE DIRECTIONS 
Summary of the overall study 
The present study demonstrates the feasibility of using computational-based 
screening and inhibitor design as a platform to identify or develop inhibitors of STAT3, 
and a tandem evaluation technique to confirm the mechanism of STAT3 inhibition is by 
targeting the DBD. In general, strategies for targeting the activity of transcription factors 
have focused on inhibiting the activating domain. Targeting the SH2 domain of STAT3 
has remained challenging and only moderately successful because of the properties a 
small molecule must have to disrupt such a large surface area. The less extensively 
explored DBD of STAT3 poses an opportunity to overcome some of these challenges. 
As previously stated, the ability of STAT3 to induce transcription regardless of 
phosphorylation and/or dimerization status also makes the DBD an ideal target for 
inhibiting STAT3 transcriptional activity. 
I began by screening commercially available compound libraries to identify a 
potential lead candidate. From the crystal structure of STAT3, there were two possible 
binding sites detected within the region of the protein where DNA binds. The initial in 
silico screen docked the Selleckchem compound libraries in the binding site that 
corresponded with residues classified as the linker domain, although this domain also 
contained residues that interact with DNA. Based on the tertiary structure of this binding 
site, there appeared to be a deeper cavity where molecules could potentially bind as 
well as some structural rigidity to maintain the opening of the target binding site to allow 
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access of small molecule inhibitors. The top hit from this screen was raf265 derivative, a 
compound with no proposed molecular target, a promising binding orientation, and 
potential for derivatization to improve residue interactions. Initial results were promising, 
as raf265 derivative had no affinity for the SH2 domain in the FP assay. However, 
examination of this compound’s inhibitory potential for the DBD of STAT3 in an EMSA 
revealed this compound increased STAT3/DNA-binding. The limitation of this evaluation 
method was that cells were dosed with raf265 derivative and then nuclear extracts 
prepared for EMSA, indicating the observed results may not be solely related to 
interactions with STAT3. The unanticipated result of raf265 derivative prompted the 
need for additional screening techniques to validate the computational model. 
Upon further investigation, few techniques for evaluating STAT3 DBD inhibitors 
in a cell-free system were established. This posed a problem for elucidating SARs and 
gave no protein:ligand interaction information for rational drug design. Several groups 
had reported dosing prepared nuclear extracts containing active STAT3 dimers with 
compounds prior to EMSA evaluation [11, 79-81]; however, this technique could not 
regulate the amount of total STAT3 in a sample. Furthermore, unless the EMSA used a 
radioactive transcription factor probe the results of the assay were not quantitative. The 
lack of a reliable and quantitative assay that evaluated the inhibitory potential of a small 
molecule against the DBD of STAT3 presented an opportunity to establish a novel 
screening approach for identifying and ranking STAT3 inhibitors. 
The addition of recombinant, monomeric STAT3 protein to a DNA-binding ELISA 
established a cell-free system to assess STAT3 DBD inhibitors. Using previously 
identified STAT3 small molecule inhibitors with differing modes of action as molecular 
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probes, we designed a tandem screening approach using the recombinant FP and 
ELISA assays to corroborate reported modes of action and create a method for 
identifying new inhibitors of the DBD of STAT3. The use of the recombinant ELISA is an 
essential addition to the field of targeting STAT3 activity as it allows for rapid 
identification of small molecule inhibitors that target the DBD. While other methods have 
been proposed using recombinant STAT3 [142, 175], the recombinant ELISA is a 
modified commercially available colorimetric assay that can then be used to standardize 
the reporting of IC50s against the STAT3 DBD. This is necessary because previous 
methods of reporting were generally cell-, tumor-, or assay-dependent. The model 
dependency of compound activities was supported when I examined different classes of 
STAT3 inhibitors in the tandem screening approach. S3I-201, an SH2 domain inhibitor, 
also had activity against the DBD and compound A26, a reported DBD inhibitor, was 
revealed to be a potent SH2 domain inhibitor. The ability to have two recombinant 
assays to evaluate the two primary domains of STAT3 targeted by small molecules will 
allow compounds to be compared globally rather than unilaterally. 
Niclosamide had previously been suggested to target the DBD, and with the 
recombinant assays our data supports this mode of action. Since another group had 
examined the alternative binding site in the DBD [175], we docked niclosamide in both 
DBD sites and elucidated structures that potentially would enhance or diminish affinity 
for either site. Based on docking scores, the traditionally classified DBD appeared more 
favorable despite its flexible tertiary protein structure. In order to increase diversity, an 
additional computational screening method was employed to identify small molecules to 
test against the DBD of STAT3. Of the ~30 compounds tested, two compounds were 
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successfully identified as STAT3 DBD inhibitors. It is worth noting that compound 10 
has previously been synthesized, and compound 19 is a novel small molecule. While 
compound 19 is twice as potent as niclosamide in cells, it did not have statistically 
different activity in the recombinant ELISA. The limitations presented by niclosamide 
and its solubility properties may be an explanation to this observable difference. 
Originally designed to treat intestinal parasites, the relative insolubility of niclosamide 
was a favorable drug property because it limited its range of exposure primarily to the 
digestive tract when administered orally. As a cancer therapy, this solubility property is 
less favorable for biodistribution. Compound 19, as a niclosamide analog, also 
displayed mild insolubility properties. Therefore, compound 19 is useful as a molecular 
tool but may not be a favorable candidate to carry through full preclinical development 
for cancer treatment.  
Future Directions 
While compound 19 was identified as a potent STAT3/DNA-binding inhibitor in 
the cell-based ELISA, the exact location of binding on STAT3 remains undefined. A co-
crystal structure of 19 and STAT3 would identify exact location of interaction, however 
this would not be a trivial endeavor. Compound 19 potently inhibits STAT3/DNA-
binding, but additional assessment of its ability to impact downstream targets of STAT3 
related to cancer progression and metastasis will need to be examined. While 19 was 
successful in inducing apoptosis in cells following 24-hour exposure, it did not show any 
synergistic effects when co-treated with cisplatin. Additionally, at 48-hour exposure 19 
and the other STAT3 inhibitors niclosamide and 10 reduced the effect of cisplatin on 
apoptosis when cells were treated concurrently. This may be due to cells moving away 
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from apoptosis and the combination therapy at longer exposure time becomes cytotoxic 
to the point of inducing necrosis. Further investigation is warranted for this observation. 
STAT3 inhibitors have been demonstrated to be effective as single treatments, 
but have also demonstrated added benefits when used as a combination therapy. 
Although we examined combination therapy with chemotherapy agent cisplatin, 
additional co-therapies may give a greater desired effect. A screen of STAT3 inhibitors 
as a combination therapy with the FDA-approved drug library would identify potential 
co-treatment compounds that display synergistic effects related to cell death and/or 
apoptosis of tumor cells. The promiscuity of STAT3 and the ability of tumor cells to 
overcome inhibition of a single transcription factor would suggest the combination of a 
STAT3 inhibitor with an additional signaling cascade inhibitor may maximize anti-tumor 
efficacy. Alternatively, combination therapy of 19 with another class of STAT3 inhibitor 
such as AZD9150, an anti-sense STAT3 inhibitor with demonstrated success of 
antitumor activity [176]. Targeting both the production of STAT3 and its transcriptional 
activity has the potential to improve clinical outcomes, especially in the case of STAT3-
mediated chemotherapy resistant tumors. 
Following additional experiments related to the impact of 19 on cells and 
downstream targets of STAT3, it would be prudent to examine the affinity of this 
compound for STAT3 over STAT1 and STAT5. The ability of STAT3 to heterodimerize 
with other STAT family members as well as the role of STAT1 as a tumor suppressor 
[177] indicates the need to determine STAT3 specificity over the other members of the 
STAT family of transcription factors. Active Motif also offers transcription factor DNA-
binding ELISAs for the other STATs and it would be interesting to see if recombinant 
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protein of STAT1 and STAT5 can be incorporated into these assays to compare the 
affinity of 19 for their DBDs. If feasible, this presents an additional facet of our proposed 
tandem screening approach and allows the IC50s generated to be comparable as they 
were obtained from the same assay type. 
This study only examined the impact of minor modifications to niclosamide and 
future development of this molecule should be performed. The combination of 10 and 
19 to produce the N-methylated version of 19 would provide additional binding 
information based on activity of this compound in the ELISAs and may support the 
hypothesis that 19 binds in both sites within the DBD while 10 only binds in the site 
within the LD. Additional iterations of niclosamide should also be designed to evaluate 
additional side chains with similarities to 19, replacing the furan with unsubstituted and 
substituted 5-membered heterocycles such as oxazoles, imidazoles, or pyrroles to 
further develop SAR. Analogs that address the solubility properties of niclosamide, 
either through further structural modifications or the development of solubility enhancing 
prodrugs or alternative formulations should be pursued. Replacement of the nitro group 
is desirable to improve inhibitor solubility while also reducing potential cardiotoxicity, 
however deletion of this functional group results in decreased potency of inhibitors. 
Alternative functional groups such as sulfonates, cyano, or similar could be examined. 
Additionally, further development of the FP and recombinant ELISA assays to be 
compatible with mid-throughput screening would allow for the physical screening of 
compound libraries to identify STAT3 DBD inhibitors that are not based on the 
niclosamide template.  
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The scope of this thesis was to perform preliminary SAR studies to identify the 
target site within the DBD of STAT3 and to potentially elucidate an alternative lead 
compound for further optimization. This objective was completed with mild success, 
however in the realm of drug discovery this thesis established the foundation for a much 
larger drug discovery and development project. Based on the data presented in this 
thesis, a definitive identification of the linker domain or the DBD as the STAT3 binding 
site for these compounds cannot be determined. Further compounds designed to 
interact with one site over the other may reveal the binding site. Alternatively, 
compounds may bind both binding sites and for inhibitory activity this may be required. 
The further development of STAT3 inhibitors may allow for affinity labeling studies and 
the resolution of a STAT3-inhibitor co-crystal structure. 
Finally, 19, its potential analogs, and additional DBD inhibitors should be 
incorporated into additional computational studies in order to predict associated 
toxicities prior to use in an animal model. Maestro10.2 and similar modeling programs 
have the ability to examine compound substructures and identify potential off-target 
toxicities. Additionally, in silico absorption, distribution, metabolism, and excretion 
(ADME) screening can be performed and bioavailability of these compounds can be 
predicted. Discovery studio has the ability to analyze compounds and predict blood 
brain barrier penetration coefficients, and it would be pertinent to examine the potential 
of the compounds to access the CNS, especially for their use as STAT3 inhibitors in 
GBM or similar tumor types. 
In conclusion, we have developed a recombinant STAT3 tandem screening 
approach to identify small molecules that target the SH2 or DBD of STAT3. Using 
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computational-based drug design, chemical synthesis, and this tandem screening 
approach we have identified two additional potent STAT3 DBD inhibitors. Further 
investigation of the niclosamide analogs will elucidate their potential to mitigate STAT3-
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